Gastric inhibitory peptide receptor ligands with bio-distribution modifier

Abstract

The present invention is related to a compound comprising a cyclic peptide of formula (la) or a cyclic peptide of formula (lb), each comprising an N-terminal modification group A comprising a bio-distribution modifier, wherein the N-terminal modification group A is attached to Xaa1, and each comprising a C-terminal group C-term comprising a bio-distribution modifier, wherein the C-terminal group C-term is attached to Xaa11.

Description

[0001] 3B Pharmaceuticals GmbH Our ref.: D 10043 PCT Gastric Inhibitory Peptide Receptor Ligands with Bio-Distribution Modifier FIELD OF THE INVENTION The present invention is related to a chemical compound; a peptide; a Gastric Inhibitory Peptide Receptor (GIPR) binding compound; a Gastric Inhibitory Peptide Receptor (GIPR) binding peptide; a composition comprising the compound; a composition comprising the Gastric Inhibitory Peptide Receptor (GIPR) binding compound; a composition comprising the peptide; a composition comprising the Gastric Inhibitory Peptide Receptor (GIPR) peptide; the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the Gastric Inhibitory Peptide Receptor (GIPR) peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, Gastric Inhibitory Peptide Receptor (GIPR) peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease which is also referred to as “thera(g)nosis” or “thera(g)nostics”; the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the Gastric Inhibitory Peptide Receptor (GIPR) binding peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a Gastric Inhibitory Peptide Receptor (GIPR) to a cell, preferably a GIPR overexpressing tumor cell or pancreatic beta cell; a method for the diagnosis of a disease using the compound, Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the Gastric Inhibitory Peptide Receptor (GIPR) binding peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the Gastric Inhibitory Peptide Receptor (GIPR) binding peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease which is also referred to as “thera(g)nosis” or “thera(g)nostics”, using the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the binding peptide and the compositions, respectively; a method for the delivery of a radionuclide to a Gastric Inhibitory Peptide Receptor (GIPR) expressing tissue using the compound, the Gastric Inhibitory Peptide Receptor (GIPR) binding compound, the peptide, the Gastric Inhibitory Peptide Receptor (GIPR) binding peptide and the compositions, respectively. BACKGROUND The human gastric inhibitory polypeptide (GIP) is a 42 amino acid incretin hormone (H-Tyr- Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asn-Phe- Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln- OH) (SEQ ID NO: 2) secreted from the enteroendocrine K-cells, which forces diet-related insulin secretion via the GIPR signaling cascade (Cho et al., Vitam Horm, 2010, 84, 111-150). It was first discovered during cholecystokinin studies by John Brown and Raymond Pederson in the 1970s (Brown et al., Scand J Gastroenterol, 1970, 5, 537-541). The GIPR is a 7-transmembrane spanning class B1 G-protein coupled receptor (GPCR) (Fredriksson et al., Mol Pharmacol, 2003, 63, 1256-1272), which is expressed in the gastrointestinal tract and the pancreatic islet cells (Usdin et al., Endocrinology, 1993, 133, 2861-2870). The extra-cellular N-terminal domain recognizes the ligand on its middle or C- terminal part, followed by the N-terminal part docking into the transmembrane domain of the receptor (Parthier et al., Proc Natl Acad Sci U S A, 2007, 104, 13942-13947). Receptor conformation induces transcription of the pro-insulin gene and insulin release by activating the adenylyl cyclase pathway that increases intracellular cyclic adenosine 3´ 5´-monophasphate (cAMP) which is associated with elevated Ca2+ influx (Ding et al., Diabetes, 1997, 46, 615- 621). Also, proliferative and anti-apoptotic effects were triggered by activation of the mitogen- activated protein kinase (MAPK) pathway and inhibition of caspase 3 (Khan et al., Peptides, 2020, 125, 170201). Both GIP(1-42)NH2 and GIP(1-30)NH2 are GIPR agonists and substrates for the dipeptidyl peptidase-4 (DPP4) resulting in potent GIPR inhibitors (GIP(3-42)NH2; GIP(3-30) NH2). While N-terminal truncations lead to decreased receptor activation and antagonism (Hansen et al., Br J Pharmacol, 2016, 173, 826-838), C-terminal modifications have only minor impact on stability or tissue distribution. Recently, the GIPR came into the focus for peptide receptor radionuclide therapy (PRRT). In contrast to non-cancerous tissues, the GIPR is highly expressed in several subgroups of neuroendocrine neoplasms (Waser et al., J Clin Endocrinol Metab, 2012, 97, 482-488). In 2012, a study showing a high GIP Receptor expression in gastroenteropancreatic and bronchial neuroendocrine tumors was published (Waser et al., J Clin Endocrinol Metab, 2012, 97, 482-488). The authors claimed GIPR represents a novel molecular target for clinical applications such as in vivo scintigraphy and targeted radiotherapy. WO 2012 / 168464 described a method for imaging and therapy of endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors by targeting GIPR. The receptor’s incidence and density in human neuroendocrine tumors and non-neoplastic tissues was analyzed by autoradiography. Of these tumors, functional pancreatic neuroendocrine tumors, including insulinomas, gastrinomas, glucagonomas and vipomas, as well as non-functional pancreatic NETs and ileal NETs, presented highest receptor expression. In non-neoplastic tissues the highest expression was found in islets of the human pancreas. Academic groups published studies in which radio- labelled GIP analogs were used for nuclear medicine imaging applications (Gourni et al., J Nucl Med, 2014, 55, 976-982; Willekens et al., Sci Rep, 2018, 8, 2948). As proof of concept these studies have been successful, however, tumor uptake of the labeled peptides was around 20x lower when compared to kidney uptake. DETAILED DESCRIPTION OF THE INVENTION The problem underlying the present invention is the provision of a compound which is suitable as a diagnostic agent and / or a therapeutic agent, particularly if conjugated to a diagnostically and / or therapeutically active radionuclide. A further problem underlying the present invention is the provision of a compound which is suitable as a diagnostic agent and / or a therapeutic agent, particularly if conjugated to a diagnostically and / or therapeutically active radionuclide, having a pEC50 of equal to or greater than 8.0 and / or a pIC50of equal to or greater than 7.5 for Gastric Inhibitory Peptide Receptor (GIPR). A further problem underlying the present invention is the provision of a compound which is suitable as a diagnostic agent and / or a therapeutic agent, particularly if conjugated to a diagnostically and / or therapeutically active radionuclide, in the diagnosis and / or therapy of a disease where the diseased cells and / or diseased tissues express Gastric Inhibitory Peptide Receptor (GIPR). A still further problem underlying the instant invention is the provision of a compound which is suitable for delivering a diagnostically and / or therapeutically effective radionuclide to a diseased cell and / or diseased tissue, respectively, and more particularly a GIPR-expressing diseased cell and / or diseased tissue, preferably the diseased tissue comprises cancer or tumor cells. Also, a problem underlying the present invention is the provision of a method for the diagnosis of a disease, of a method for the treatment and / or prevention of a disease, and a method for the combined diagnosis and treatment of a disease; preferably such disease is a disease involving GIPR-expressing cells and / or tissues, more particularly a GIPR-expressing diseased cell and / or diseased tissue, preferably the diseased tissue comprises or contains cancer or tumor cells or pancreatic beta cells. A still further problem underlying the present invention is the provision of a method for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, a method for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of a disease; preferably, the disease is cancer, more preferably the disease is a neuroendocrine tumor. Also, a problem underlying the present invention is the provision of a pharmaceutical composition containing a compound having the characteristics as outlined above. Furthermore, a problem underlying the present invention is the provision of a kit which is suitable for use in any of the above methods. These and other problems are solved by the subject matter of the attached independent claims; preferred embodiments may be taken from the attached dependent claims. These and other problems are also solved by the subject matter of the following Embodiments. Embodiment 1. A compound comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib) each comprising an N-terminal modification group A attached to Xaa1, and each comprising a C-terminal group C-term attached to Xaa11, wherein the peptide sequence is drawn from left to right in N- to C-terminal direction, the N-terminal modification group A comprises a Z group, wherein a linker is optionally interspersed between the Z group and Xaa1, wherein the Z group comprises a bio-distribution modifier, Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, wherein the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2, Xaa2 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa2 is a residue of an α-amino acid with a side chain comprising a heteroaryl ring, wherein the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3, Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring, wherein the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4, Xaa4 is a residue of an α-amino acid optionally comprising a Z group or is a residue of an N-alkylated α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5, Xaa5 is a residue of an α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6, Xaa6 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group, wherein the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7, Xaa7 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, wherein the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8, Xaa8 is a residue of an α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9, Xaa9 is a residue of an α-amino acid, wherein the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10, Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring, wherein the carbonyl group of Xaa10 is covalently attached to the α-nitrogen atom of Xaa11, Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, the C-terminal modification C-term comprises a Z group, wherein a linker is optionally interspersed between the Xaa11 and the Z group, wherein the Z group comprises a bio-distribution modifier, wherein Xaa7 and Xaa11 are indirectly linked or directly covalently linked to each other forming a macrocyclic ring, wherein if Xaa7 and Xaa11 are indirectly linked forming a cyclic peptide of formula (Ia), the heteroatom of Xaa7 and the heteroatom of Xaa11 are linked through a ring interspersed between the heteroatom of Xaa7 and the heteroatom of Xaa11 forming Yc, wherein the ring is a heteroaryl ring, an aryl ring optionally comprising a Z group or a heterocyclic ring, wherein the heteroatom is each and individually selected from the group consisting of a sulfur atom and a nitrogen atom, wherein if the heteroatom of Xaa7 is a sulfur atom, a thioether bond covalently links Xaa7 to the ring, if the heteroatom of Xaa7 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa7 to the ring, if the heteroatom of Xaa11 is a sulfur atom, a thioether bond covalently links Xaa11 to the ring, and if the heteroatom of Xaa11 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa11 to the ring, or wherein if Xaa7 and Xaa11 are directly covalently linked forming a cyclic peptide of formula (Ib), the heteroatom of Xaa7 is a sulfur atom and the heteroatom of Xaa11 is a sulfur atom forming a disulfide bond, and wherein each and any of the bio-distribution modifiers of the N-terminal modification group A, Xaa4, Xaa5 and Xaa8 comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group wherein, if the bio-distribution modifier is comprised by the N-terminal modification group A, (a) the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the α-nitrogen atom of Xaa1, or (b) if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier and Xaa1, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the linker and the carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1, or wherein, if the bio-distribution modifier is comprised by Xaa4 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa4, or wherein, if the bio-distribution modifier is comprised by Xaa5 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa5, or wherein, if the bio-distribution modifier is comprised by Xaa8 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa8, and wherein the bio-distribution modifier comprised by the C-terminal modification group C-term comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the side chain of the α-amino acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein (a) the carbonyl group of Xaa11 is covalently attached to the α-nitrogen atom of the α-amino acid of the bio-distribution modifier, or (b) if a linker comprising an amino group and a carbonyl group is interspersed between the Xaa11 and the bio-distribution modifier, the carbonyl group of Xaa11 is covalently attached to the amino group of the linker and the carbonyl group of the linker is covalently attached to the α-nitrogen atom of the α-amino acid, and wherein to the carbonyl group of the α-amino acid of the bio-distribution modifier an amino group is covalently attached thereby forming an amide. Embodiment 2. The compound of Embodiment 1, wherein Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, preferably Xaa1 is a residue of an α-amino acid of formulae (IIa), (IIb) or (IIc), more preferably Xaa1 is a residue of an α-amino acid of formula (IIa), wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom of Xaa1, or if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1, R1a is selected from the group consisting of H and (C1-C4)alkyl, R1b is selected from the group consisting of CO2H, SO3H, OPO3H2, CONH2and OH, R1c is selected from the group consisting of H, OH and (C1-C2)alkyl under the proviso that R1b is selected from the group consisting of CO2H, SO3H and CONH2, or is selected from the group consisting of H and (C1-C2)alkyl under the proviso that R1b is selected from the group consisting of OH and OPO3H2, R1d is selected from the group consisting of H and (C1-C2)alkyl, preferably if R1c is (C1-C2)alkyl, R1d is the same (C1-C2)alkyl, R1e is selected from the group consisting of H, OH and (C1-C2)alkyl, R1f is selected from the group consisting of H and (C1-C2)alkyl, preferably if R1e is (C1-C2)alkyl, R1f is the same (C1-C2)alkyl, and the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2, Xaa2 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa2 is a residue of an α-amino acid of formulae (IIIa) or (IIIb), more preferably a residue of an α-amino acid of formula (IIIa), wherein X2a is selected from the group consisting of NH, NCH3and S, preferably selected from the group consisting of NH and S, X2b is selected from the group consisting of N, C-H, C-F and C-CH3, preferably selected from the group consisting of N and C-H, R2a is selected from the group consisting of H, a halogen, methyl and OCH3, preferably R2a is selected from the group consisting of H and F, R2b is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2b is selected from the group consisting of H, Cl and Br, R2c is selected from the group consisting of H, OH, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of F, Cl and Br, more preferably R2c is selected from the group consisting of H, F and OH, R2d is selected from the group consisting of H, a halogen, methyl and OCH3, wherein the halogen is selected from the group consisting of F, Cl and Br, preferably R2d is H, R2e is selected from the group consisting of H, a halogen and methyl, preferably the halogen is Cl, more preferably R2e is H, R2f is selected from the group consisting of H and OCH3, preferably R2f is H, R2g is selected from the group consisting of H, OH, methyl and OCH3, preferably R2g is H, or (b), under the proviso that Xaa3 is of formulae (IVa) or (IVb), preferably under the proviso that Xaa3 is of formula (IVa), Xaa2 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an aryl ring, preferably Xaa2 is a residue of an α-amino acid of formula (IIIc) wherein R2h is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2h is H, Cl or Br, R2i is selected from the group consisting of H, methyl, C(CH3)3, CF3, OH, OCH3, OCH2CH3,OCF3, CONH2, CO2H and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2i is selected from the group consisting of H, Cl and Br, R2k is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2k is selected from the group consisting of H, Cl and Br, R2m is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2m is selected from the group consisting of H, Cl and Br, and the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3, Xaa3 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa3 is a residue of an α-amino acid of formulae (IVa) or (IVb), more preferably Xaa3 is a residue of an α-amino acid of formula (IVa), wherein X3a is selected from the group consisting of NH, NCH 3a 3 and S, preferably X is selected from the group consisting of NH and S, X3b is selected from the group consisting of C-H, C-F, C-Cl, C-Br, C-CH3, C-OCH3 and N, preferably X3b is selected from the group consisting of C-H and C-F, X3c is selected from the group consisting of C-H and N, preferably X3c is C-H, R3b is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of F and Cl, more preferably R3b is selected from the group consisting of H and F, R3c is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of Cl, Br and F, more preferably R3c is selected from the group consisting of Cl and Br, R3d is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is F, R3e is selected from the group consisting of H, a halogen and methyl, preferably the halogen is Cl, R3f is selected from the group consisting of H and OCH3, R3g is selected from the group consisting of H, F, OH, methyl and OCH3, or (b) under the proviso that Xaa2 is an amino acid residue of formula (IIIa), Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an aryl ring, preferably Xaa3 is a residue of an α-amino acid of formulae (IVc) or (IVd) wherein R3h is selected from the group consisting of a halogen, OH, methyl, CF3, OCH3, OCF3 and CONH2, preferably the halogen is selected from the group consisting of Cl and Br, R3i is selected from the group consisting of a halogen, OH, methyl, CF3, OCH3, OCF3 and CONH2, preferably the halogen is selected from the group consisting of Cl and Br, and the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4, Xaa4 is (a) a residue of a cyclic non-aromatic α-amino acid, preferably Xaa4 is a residue of an α-amino acid of formula (Va) wherein R4a is selected from the group consisting of H, OH, methyl and CF3, R4b is selected from the group consisting of H and methyl, preferably R4b is methyl if R4a is methyl, X4 is selected from the group consisting of CHR4c, S and O, wherein R4c is selected from the group consisting of NH2, OH, H, NHR4d, methyl and F, preferably R4c is NH2or OH, wherein R4d is selected from the group consisting of Ac and a Z group, m is 1 or 2, preferably m is 1, or (b) a residue of an N-alkylated α-amino acid, preferably Xaa4 is a residue of an N-alkylated α-amino acid of formula (Vb) wherein n is 0, 1, 2, 3, 4, or 5, preferably n is 0, 1 or 3, R4e is, if n is 0, selected from the group consisting of H, methyl, an aryl ring, COOH, CONH 4h 2 and C(=O)R , or is, if n is 1, 2, 3, 4 or 5, selected from the group consisting of H, methyl, an aryl ring, OH, NH 4h 2, COOH, CONH2 and NHR , R4f is selected from the group consisting of H and (C1-C2)alkyl, R4g is selected from the group consisting of H and methyl, R4h is a Z group, preferably the Z group is a bio-distribution modifier, or (c) Xaa4 is a residue of a bicyclic non-aromatic α-amino acid, preferably Xaa4 is a residue of a bicyclic non-aromatic α-amino acid of formula (Vc) wherein o is 1 or 2, and the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5, Xaa5 is (a) a residue of an α-amino acid optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by (C1-C4)alkyl or (b) a cyclic α-amino acid, and the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6, Xaa6 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group, preferably Xaa6 is a residue of an α-amino acid of formula (VIIa) wherein p is 1, 0 or 2, preferably p is 1, R6a is (C1-C2)alkyl, R6b is methyl, R6c is H, if p is 0, or is selected from the group consisting of H and methyl, if p is 1 or 2, and the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7, Xaa7 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa7 is a residue of an α-amino acid of formula (VIIIa) wherein X7 comprises the heteroatom and is selected from the group consisting of – S– and –NH–, is 1 or 2, preferably q is 1, and the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8, Xaa8 is (a) a residue of an aliphatic cyclic α-amino acid, of an aliphatic heterocyclic α-amino acid or of an aliphatic cyclic α-amino acid comprising an annulated aromatic ring, preferably Xaa8 is a residue of an α-amino acid of formula (IXa) or (IXb), more preferably Xaa8 is a residue of an α-amino acid of formula (IXa), wherein X8 is selected from the group consisting of NR8a, O, NH, and CH2, wherein R8a is a Z group or R8a is acetyl, wherein if R8a is a Z group, the Z group preferably is a chelator optionally comprising a linker, r is 2 or 1, preferably r is 2, s is 1 or 2, preferably s is 1, t is 1 or 2, preferably t is 1 if s is 1, and t is 2 if s is 2, or (b) a residue of an α-amino acid or an α-alkyl-α-amino acid, preferably Xaa8 is a residue of an α-amino acid of formula (IXc), wherein R8b is selected from the group consisting of H, OH, NH 8e 2, NHR , (C1-C2)alkyl, COOH, CONH2, an aryl ring and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indoyl, wherein R8e is a Z group, preferably the Z group is a chelator optionally comprising a linker, R8c is selected from the group consisting of H and methyl, if R8b is selected from the group consisting of OH, NH 8e 2 and NHR , or is selected from the group consisting of H, methyl and OH, if R8b is selected from the group consisting of H, (C1-C2)alkyl, COOH, CONH2, an aryl ring and a heteroaryl ring, R8d is selected from the group consisting of H and (C1-C2)alkyl, u is 0, 1, 2, 3, 4, or 5, preferably u is 0, 1 or 3, and the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9, Xaa9 is a residue of an acyclic α-amino acid, wherein the acyclic α-amino acid is inL-configuration and the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10, Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring, preferably Xaa10 is a residue of an α-amino acid of formula (XIa), wherein R10a is selected from the group consisting of (C1-C2)alkyl and phenyl, R10b is selected from the group consisting of methyl and H, R10c is selected from the group consisting of H and methyl, w is 0 or 1, and the carbonyl group of Xaa10 is covalently attached to the α-nitrogen atom of Xaa11, Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa11 is an α-amino acid of formula (XIIa), wherein X11 comprises the heteroatom and is selected from the group consisting of –S– and –NH–, R11c is the C-terminal group C-term, x is 1 or 2, and wherein a linker is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio- distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to the ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-I), wherein XA comprises a nitrogen atom, a triazolyl moiety, a hydroxymethyl- triazolyl moiety or an urea moiety, a1 is 0, 1, 2, 3, 4, 5, or 6, if XA is a triazolyl moiety, preferably a1is 2, if XA is selected from the group comprising a nitrogen atom, a hydroxymethyl-triazolyl moiety and an urea moiety, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2 is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3is 0 or 1, and b2 is 0 or 1, and RA2 is absent, if XA is selected from the group comprising a triazolyl moiety, a hydroxmethyl-triazolyl moiety and an urea moiety, or RA2 is H or a first level alkyl group of a structure of formula (A-II), if XA is a nitrogen atom, wherein a2is 0 or 1, b1 is 0 or 1, wherein if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III) or RA3 and RA4 are each H, or wherein if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein in formula (A-III) a3 is 0 or 1, and b2 is 0 or 1, and wherein the carbonyl group of the structure (A-I) is covalently attached to the α-nitrogen atom of Xaa1, or if a linker, comprising an amino group and a carbonyl group, is interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the structure (A-I) is covalently attached to the amino group of the linker, and wherein a linker is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-I), wherein XC comprises a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety or any combination thereof, a4 is 0, 1, 2, 3, or 4, if XC is a triazolyl moiety, preferably a4is 1 or 2, more preferably a4is 1 if XC is selected from the group comprising a nitrogen atom, a hydroxymethyl-triazolyl moiety and an urea moiety, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are each H, or wherein, if b3 is 1, each and any of RC3, RC4 and RC5 is selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is a second level alkyl group of a structure of formula (C-III), wherein is 0 or 1, and is 0 or 1 and RC2 is absent, if XC is selected from the group comprising a triazolyl moiety, a hydroxmethyl-triazolyl moiety and an urea moiety, or RC2 is H or is a first level alkyl group of a structure of formula (C-II), if XC is a nitrogen atom, wherein a5is 0 or 1, b3 is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are H, or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein in formula (C-III) a6is 0 or 1, and b4 is 0 or 1, and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising a carbonyl group and an amino group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably a linker is interspersed between Xaa11 and the bio-distribution comprised by the C-terminal modification group C-term. Embodiment 3. The compound of any one of Embodiments 1 and 2, wherein Xaa7 is a residue of formula (VIIIa) wherein X7 is –S– or –NH–, q is 1 or 2, preferably q is 1, Yc is a structure of formula (XIIIa) Y1 is selected from the group consisting of N and CH, Y2 is selected from the group consisting of CH and N, and Xaa11 is a residue of formula (XIIa) (XIIa), wherein X11 is –S– or –NH–, R11c is the C-terminal group C-term, is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Ic), , more preferably the compound comprises a cyclic peptide of formula (Ic), wherein X7 is –S–, X11 is –S–, Y1 is N or CH, Y2 is CH, q is 1, and x is 1, most preferably the compound comprises a cyclic peptide of formula (Ic), wherein X7 is –S–, X11 is –S–, Y1 is N, Y2 is CH, q is 1, and x is 1. Embodiment 4. The compound of Embodiment 3, wherein X7 is –S–, X11 is –S–, Y1 is N or CH, Y2 is CH, q is 1 or 2, preferably q is 1 and, x is 1 or 2, preferably x is 1. Embodiment 5. The compound of any one of Embodiments 3 and 4, wherein X7 is –S–, X11 is –S–, Y1 is N, Y2 is CH, q is 1, and x is 1. Embodiment 6. The compound of Embodiment 3, wherein Xaa7 is a residue of an α- amino acid selected from the group consisting of Cys, cys, Hcy and Dap, wherein Xaa11 is a residue selected from the group consisting of Cys, cys, Hcy and Dap, and wherein Yc is selected from the group consisting of 2Lut, 3MeBn and 3Lut. Embodiment 7. The compound of any one of Embodiments 3, 4 and 6, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is selected from the group consisting of 2Lut and 3MeBn, preferably is 2Lut. Embodiment 8. The compound of any one of Embodiments 3 to 7, preferably the compound of Embodiment 7, wherein Xaa7 is a Cys residue, wherein Xaa11 is a Cys residue, and wherein Yc is 2Lut. Embodiment 9. The compound of any one of Embodiments 3 and 6, wherein X7 is –NH– , X11 is –S–, Y1 is N or CH, preferably Y1 is N, Y2 is CH, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 10. The compound of any one of Embodiments 3 and 9, preferably the compound of Embodiment 9, wherein Xaa7 is a Dap residue, wherein Xaa11 is a residue selected from the group consisting of Cys, cys, Hcy, and wherein Yc is selected from the group consisting of 2Lut and 3MeBn, preferably Yc is 2Lut. Embodiment 11. The compound of any one of Embodiments 3 and 6, wherein X7 is –S–, X11 is –NH–, Y1 is N or CH, preferably Y1 is N, Y2 is CH, q is 1 or 2, preferably q is 1 and, x is 1 Embodiment 12. The compound of any one of Embodiments 3, 6 and 11, preferably the compound of Embodiment 11, wherein Xaa7 is a Cys or Hcy residue, preferably Xaa7 is a Cys residue, wherein Xaa11 is a Dap residue, and wherein Yc is selected from 2Lut and 3MeBn, preferably Yc is 2Lut. Embodiment 13. The compound of any one of Embodiments 3 and 6, wherein X7 is –NH– , X11 is –NH–, Y1 is N or CH, preferably Y1 is N, Y2 is CH, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 14. The compound of any one of Embodiments 3, 6 and 13, preferably the compound of Embodiment 13, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Dap residue, and wherein Yc is is selected from the group consisting of 2Lut and 3MeBn, preferably Yc is 2Lut. Embodiment 15. The compound of any one of Embodiments 1 and 2, wherein Xaa7 is a residue of formula (VIIIa) wherein X7 is –S– or –NH–, q is 1 or 2, preferably q is 1, Yc is a structure of formula (XIIIh) (XIIIh), wherein RYa is –CH2–, RYb is –CH2–, and RYc is –CH Yd 2–R , and RYd is a structure of formulae (XIIIc), (XIIId) or (XIIIe), wherein RYe and RYf are each and independently selected from the group consisting of H and (C1-C4)alkyl, i is each and independently 1, 2, 3, 4, 5 or 6, preferably i is 1 or 2, j and k are each and independently 1, 2 or 3, and X is O or S, preferably X is S, wherein in formulae (XIIIc) and (XIIIe) one of the two nitrogen atoms is covalently attached to –CH2– of RYc and in formula (XIIId) -X- is covalently attached to -CH Yc 2– of R while to the remaining nitrogen atom optionally a Z group is covalently attached, preferably the Z group comprises a chelator and optionally a linker, and Xaa11 is a residue of formula (XIIa) (XIIa), wherein X11 is –S– or –NH–, R11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Ii), , more preferably the compound comprises a cyclic peptide of formula (Ii), wherein X7 is –S– and X11 is –S–, RYc is –CH Yd 2–R , and RYd is a structure of formulae (XIIId) or (XIIIe), wherein RYf is H, i is 1, j is 1, and k is 1, wherein in formula (XIIId) –X– is S and is attached to –CH Yc 2– of R , and in formula (XIIIe) one of the two nitrogen atoms is attached to -CH2– of RYc, while to the remaining nitrogen atom in either (XIIId) or (XIIIe) optionally a Z group is covalently attached, preferably the Z group comprises a chelator and optionally a linker, q is 1, and x is 1, most preferably the compound comprises a cyclic peptide of formula (Ii), wherein RYd is a structure of formula (XIIId), wherein –X– is S and RYf is H, and i is 1. Embodiment 16. The compound of Embodiment 15, wherein Xaa7 is a Cys residue, wherein Xaa11 is a Cys residue, and wherein Yc is tMeBn(DOTA-AET) or tMeBn(DOTA-PP). Embodiment 17. The compound of any one of Embodiments 1 to 2, wherein Xaa7 is a residue of formula (VIIIa) wherein X7 is –S– or –NH–, q is 1 or 2, preferably q is 1, Yc is a structure of formula (XIIIb) (XIIIb), wherein RYa is –CH2–, RYb is –CH2–, and Xaa11 is a residue of formula (XIIa) (XIIa), wherein X11 is –S– or –NH–, R11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Id), , more preferably the compound comprises a cyclic peptide of formula (Id), wherein X7 is –S–, X11 is –S–, q is 1, and x is 1. Embodiment 18. The compound of Embodiment 17, wherein X7 is –S–, X11 is –S–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 19. The compound of any one of Embodiments 17 and 18, preferably the compound of Embodiment 18, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is 2MeBn. Embodiment 20. The compound of Embodiment 17, wherein X7 is –NH–, X11 is –S–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 21. The compound of any one of Embodiments 17 and 20, preferably the compound of Embodiment 20, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is 2MeBn. Embodiment 22. The compound of Embodiment 17, wherein X7 is –S–, X11 is –NH–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 23. The compound of any one of Embodiments 17 and 22, preferably the compound of Embodiment 22, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Dap residue, and wherein Yc is 2MeBn. Embodiment 24. The compound of Embodiment 17, wherein X7 is –NH–, X11 is –NH–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 25. The compound of any one of Embodiments 17 and 24, preferably the compound of Embodiment 24, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Dap residue, and wherein Yc is 2MeBn. Embodiment 26. The compound of any one of Embodiments 1 and 2, wherein Xaa7 is a residue of formula (VIIIb) (VIIIb), wherein q is 1 or 2, preferably q is 1, Yc is a structure of formula (XIIIg) (XIIIg), wherein RYi is selected from the group consisting of H and (C1-C6)alkyl, and Xaa11 is a residue of formula (XIIb) (XIIb), wherein R11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Ig), , more preferably the compound comprises a cyclic peptide of formula (Ig), wherein q is 1, and x is 1 or 2. Embodiment 27. The compound of Embodiment 26, wherein Xaa7 is a Cys residue, wherein Xaa7 is selected from the group comprising Cys and Hcy, and wherein Yc is mli. Embodiment 28. The compound of any one of Embodiments 1 and 2, wherein Yc is a structure of formula (XIIIf) (XIIIf), wherein RYg is –C(=O)–, RYh is –CH2–, Xaa7 is a residue of formula (VIIIa) wherein X7 is –S– or –NH– and is covalently attached to RYh, q is 1 or 2, preferably q is 1, and Xaa11 is a residue of formula (XIIa) (XIIa), wherein X11 is –NH– and is covalently attached to RYg, is the C-terminal group C-term, is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (If), , more preferably the compound comprises a cyclic peptide of formula (If), wherein X7 is –S–, q is 1, and x is 1. Embodiment 29. The compound of Embodiment 28, wherein X7 is –S–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 30. The compound of any one of Embodiments 28 and 29, preferably the compound of Embodiment 29, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Dap residue, and wherein Yc is 3CbBn. Embodiment 31. The compound of Embodiment 28, wherein X7 is –NH–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 32. The compound of Embodiment 28, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Dap residue, and wherein Yc is 3CbBn. Embodiment 33. The compound of any one of Embodiments 1 and 2, wherein Yc is a structure of formula (XIIIf) (XIIIf), wherein RYg is –C(=O)–, RYh is –CH2–, Xaa7 is a residue of formula (VIIIa) wherein X7 is –NH– and is covalently attached to RYg, q is 1 or 2, preferably q is 1, and Xaa11 is a residue of formula (XIIa) (XIIa), wherein X11 is –S– or –NH– and is covalently attached to RYh, R11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Ie), , more preferably the compound comprises a cyclic peptide of formula (Ie), wherein X11 is –S–, q is 1, and x is 1. Embodiment 34. The compound of Embodiment 33, wherein X11 is –S–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 35. The compound of any one of Embodiments 33 and 34, preferably the compound of Embodiment 34, wherein Xaa7 is a Dap residue, wherein Xaa11 is Cys or Hcy residue, and wherein Yc is 3MeBz. Embodiment 36. The compound of Embodiment 33, wherein X11 is –NH–, q is 1 or 2, preferably q is 1, and x is 1 or 2, preferably x is 1. Embodiment 37. The compound of any one of Embodiments 33 and 36, preferably the compound of Embodiment 36, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Dap residue, and wherein Yc is 3MeBz. Embodiment 38. The compound of any one of Embodiments 1 and 2, wherein the compound comprises a cyclic peptide of formula (Ib), Xaa7 is a residue of formula (VIIIc) and Xaa11 is a residue of wherein R11c is the C-terminal group C-term, preferably the compound comprises a cyclic peptide of formula (Ih), . Embodiment 39. The compound of Embodiment 38, wherein Xaa7 is a Hcy residue and Xaa11 is a Hcy residue. Embodiment 40. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 and 39, wherein Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group within the side chain, preferably Xaa1 is a residue of an α-amino acid of formulae (IId) or (IIe), more preferably Xaa1 is a residue of an α-amino acid formula (IId), wherein R1a is selected from the group consisting of H and methyl, R1b is selected from the group consisting of CO2H, CONH2, OH, SO3H and OPO3H2, and wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom Xaa1, or if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier comprised by the N- terminal modification group A and Xaa1, a carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1. Embodiment 41. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 and 40, wherein Xaa1 is a residue of an α-L-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group within the side chain, Xaa1 is a residue of an α-L-amino acid of formulae (IIf) or (IIg), preferably Xaa1 is a residue of an α-L- amino acid of formula (IIf), wherein R1a is selected from the group consisting of H and methyl, R1b is selected from the group consisting of CO2H, CONH2, OH, SO3H and OPO3H2, and wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom Xaa1, or if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier comprised by the N- terminal modification group A and Xaa1, a carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1. Embodiment 42. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, preferably the compound of Embodiment 41, wherein Xaa1 is a residue of an α-L-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group within the side chain, Xaa1 is a residue of an α-L-amino acid of formulae (IIf) or (IIg), preferably Xaa1 is a residue of an α-L-amino acid of formula (IIf), wherein R1a is H, R1b is selected from the group consisting of CO2H, CONH2, OH and SO3H, and wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom Xaa1. Embodiment 43. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 and 42, preferably the compound of Embodiment 42, wherein Xaa1 is a residue of an α-L-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar within the side chain, Xaa1 is a residue of an α-L-amino acid of formulae (IIf) or (IIg), preferably Xaa1 is a residue of an α-L-amino acid of formula (IIf), wherein R1a is H, R1b is CO2H or CONH2, and wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom Xaa1. Embodiment 44. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, wherein Xaa1 is a residue of an α-L-amino acid selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya, Pse, Nmd and Ser. Embodiment 45. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 and 44, preferably the compound of Embodiment 44, wherein Xaa1 is a residue of an α-L-amino acid selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya, and Ser. Embodiment 46. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and 45, preferably the compound of any one of Embodiments 44 and 45, wherein Xaa1 is a residue of an α-L-amino acid selected from the group consisting of Asp, Asn, Glu, and Gln. Embodiment 47. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 and 46, preferably the compound of any one of Embodiments 44 to 46, wherein Xaa1 is an Asp residue. Embodiment 48. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, wherein Xaa2 is a residue of an α-L-amino acid of formula (IIId), wherein X2a is NH or S, preferably is NH, R2a is H or F, R2b is selected from the group consisting of H, F and Cl, and R2c is selected from the group consisting of H, F, Cl, Br and OH. Embodiment 49. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48, preferably the compound of Embodiment 48, wherein Xaa2 is a residue of an α-L-amino acid of formula (IIId), wherein X2a is NH, R2a is H or F, R2b is H, R2c is H, F or OH. Embodiment 50. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48, wherein Xaa2 is a residue of an α-L-amino acid selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, Bta, 5Clw, 5Brw and 6Fw. Embodiment 51. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 and 50, preferably the compound of Embodiment 50, wherein Xaa2 is a residue of an α-L-amino acid selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, 5Clw, 5Brw and 6Fw. Embodiment 52. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 and 51, preferably the compound of any one of Embodiments 50 and 51, wherein Xaa2 is a residue of an α-L-amino acid selected from the group consisting of Trp, Hyw, 5Fw and 7Fw. Embodiment 53. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 and 52, preferably the compound of any one of Embodiment 50, 51 and 52, wherein Xaa2 is a Trp residue. Embodiment 54. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, wherein Xaa2 is 1Ni. Embodiment 55. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, wherein under the proviso that Xaa3 is of formulae (IVa) or (IVb), preferably under the proviso that Xaa3 is of formula (IVa), Xaa2 is a residue of an α-L-amino acid of formula (IIIc) wherein R2h is H or Cl, R2i is H or Cl, R2k is H or Cl, R2m is H or Cl. Embodiment 56. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 55, preferably the compound of Embodiment 55, wherein under the proviso that Xaa3 is of formula (IVa) or (IVb), preferably under the proviso that Xaa3 is of formula (IVa), Xaa2 is a residue of an α-L-amino acid selected from the group consisting of Phe, Ocf, Mcf, Pcf, Eaa, Egm, Egn and Egp. Embodiment 57. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 55 and 56, preferably the compound of any one of Embodiments 55 and 56, wherein under the proviso that Xaa3 is of formulae (IVa) or (IVb), preferably under the proviso that Xaa3 is of formula (IVa), Xaa2 is a residue of an α-L-amino acid selected from the group consisting of Mcf and Egp. Embodiment 58. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 and 57, wherein Xaa3 is a residue of an amino acid of formula (IVe) or (IVf), wherein R3b is H or F, R3c is selected from the group consisting of Cl, Br, H and F, X3a is NH or S, X3b is selected from the group consisting of C-H, C-F and N, and X3c is C-H or N, preferably X3c is C-H. Embodiment 59. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 and 58, preferably the compound of Embodiment 58, wherein Xaa3 is a residue of an amino acid of formula (IVg) wherein R3b is H or F, and R3c is selected from the group consisting of Cl, Br, and H. Embodiment 60. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 and 57, wherein Xaa3 is a residue of an α-L-amino acid selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw, 7Fw, 6Clw and 7Nw. Embodiment 61. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58 and 60, preferably the compound of any one of Embodiments 58 and 60, wherein Xaa3 is a residue of an α-L-amino acid selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw and 7Fw. Embodiment 62. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 and 61, preferably the compound of any one of Embodiments 58, 59, 60 and 61, wherein Xaa3 is a residue of an α-L-amino acid selected from the group consisting of 5Clw and 5Brw. Embodiment 63. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 and 62, preferably the compound of any one of Embodiments 58, 59, 60, 61 and 62, wherein Xaa3 is a 5Clw residue. Embodiment 64. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 and 54, wherein under the proviso that Xaa2 is of formulae (IIIa) or (IIIb), preferably under the proviso that Xaa2 is of formula (IIIa), Xaa3 is a residue of an α-L-amino acid acid of formulae (IVc) or (IVd) wherein R3i and R3h each and independently is Cl. Embodiment 65. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 and 64, preferably the compound of Embodiment 64, wherein under the proviso that Xaa2 is of formulae (IIIa) or (IIIb), preferably under the proviso that Xaa2 is of formula (IIIa), Xaa3 is Eaa or Egp. Embodiment 66. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65, wherein Xaa4 is a residue of an α-L-amino acid of formula (Va) wherein m is 1 or 2, preferably m is 1, R4a is selected from the group consisting of H, OH and methyl, R4b is either H or methyl, preferably R4b is methyl if R4a is methyl, X4 is selected from the group consisting of CHR4c, CH2, S and O, wherein R4c is selected from the group consisting of NHR4d, NH2, H, OH, methyl and F, wherein R4d is Ac or is a Z group, preferably the Z group is a chelator optionally comprising a linker, more preferably the chelator is DOTA. Embodiment 67. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66, preferably the compound of Embodiment 66, wherein Xaa4 is a residue of an α-L-amino acid of formula (Vd) wherein R4a is selected from the group consisting of H, OH and methyl, R4b is H or methyl, preferably R4b is methyl, if R4a is methyl, R4i is selected from the group consisting of NH 4d 2, OH, NHR , H and F, wherein R4d is H, Ac, or is a Z group, if the Z group is a chelator comprising an optional linker, preferably the chelator is DOTA. Embodiment 68. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 and 67, preferably the compound of any one of Embodiments 66 and 67, wherein Xaa4 is a residue of an α-L-amino acid of formula (Ve) wherein R4i is selected from the group consisting of NH2, OH and H. Embodiment 69. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66, preferably the compound of Embodiment 66, wherein Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), 4Tfp, H3p, Eaz, Oxa, Dtc and Pip. Embodiment 70. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 and 69, preferably the compound of any one of Embodiments 66 and 69, wherein Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), 4Tfp, H3p, Eaz, Oxa and Dtc. Embodiment 71. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69 and 70, preferably the compound of any one of Embodiments 66, 67, 69 and 70, wherein Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), 4Tfp and H3p. Embodiment 72. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, preferably the compound of any one of Embodiments 66, 67, 68, 69, 70 and 71, wherein Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro and 4Ap. Embodiment 73. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 and 72, preferably the compound of any one of Embodiments 66, 67, 68, 69, 70, 71 and 72, wherein Xaa4 is a Tap residue. Embodiment 74. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 and 72, preferably the compound of any one of Embodiments 66, 67, 68, 69, 70, 71 and 72, wherein Xaa4 is a Hyp residue. Embodiment 75. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 and 72, preferably the compound of any one of Embodiments 66, 67, 68, 69, 70, 71 and 72, wherein Xaa4 is a Pro residue. Embodiment 76. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65, wherein Xaa4 is a residue of an N-alkylated α-amino acid of formula (Vf) wherein n is 0, 1 or 3, R4e if n = 0, is selected from the group consisting of H and phenyl, or if n = 1, is selected from the group consisting of methyl, CONH2 and COOH, or if n = 3, is selected from the group consisting of NH 4h 4h 2 and NHR , wherein R is a Z group, preferably the Z group is a bio-distribution modifier, R4f is selected from the group consisting of H and methyl. Embodiment 77. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 76, preferably the compound of Embodiment 76, wherein Xaa4 is a residue of an N-alkylated α-amino acid selected from the group consisting of Nmg, Nlys, Nleu, Nphe and Nglu. Embodiment 78. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65, wherein Xaa4 is an Oic residue. Embodiment 79. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 and 78, wherein Xaa5 is a residue of an α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio- distribution modifier, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by a methyl group. Embodiment 80. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 and 79, preferably the compound of Embodiment 79, wherein Xaa5 is a residue of an α-amino acid of formulae (VIa) or (IVb), preferably Xaa5 is a residue of an α-amino acid of formula (VIa), wherein R5a is selected from the group comprising H, COOH, SO3H, OPO3H, CONH2, OH, NH2, NHR5d, NHC(=NH)NH2, (C1-C4)alkyl , an aryl ring and a heteroaryl ring, wherein R5d is a Z group, preferably the Z group is a bio-distribution modifier, and wherein preferably the aryl ring is phenyl, and wherein preferably the heteroaryl ring is 3-indoyl or 4-imidazoyl, preferably R5a is COOH, R5b is selected from the group consisting of H and methyl, preferably R5b is H, d is 1, 2, 3, 4, or 5, preferably d is 2, R5c is selected from the group consisting of H and OH, e is 1 or 2. Embodiment 81. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80, preferably the compound of any one of Embodiments 79 and 80, wherein Xaa5 is a residue of an α-amino acid of formula (VIa), wherein R5a is selected from the group comprising COOH, CONH2, OH, NH2, NHC(=NH)NH2 and a heteroaryl ring, wherein preferably the heteroaryl ring is 3-indoyl or 4-imidazoyl, preferably R5a is COOH, d is 1, 2, 3, 4, or 5, preferably d is 2, R5b is H. Embodiment 82. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 and 81, preferably the compound of any one of Embodiments 79, 80 and to 81, wherein Xaa5 is a residue of an α- amino acid of formula (VIa), wherein R5a is selected from the group comprising COOH, CONH 5a 2 and OH, preferably R is COOH, d is 1, or 2, preferably d is 2. Embodiment 83. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82, preferably the compound of any one of Embodiments 80, 81 and 82, more preferably the compound of Embodiment 82, wherein the stereo configuration of Xaa5 is the L-configuration or is the D-configuration, preferably the stereo configuration of Xaa5 is the L-configuration. Embodiment 84. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80, preferably the compound of any one of Embodiments 79 and 80, wherein Xaa5 is a residue of an α-amino acid selected from the group consisting of Glu, Gln, Asp, Asn, Ser, Hse, Pse, Nme, glu, Ala, Trp, Lys, Arg, His, Hly, Har, Val and Phe. Embodiment 85. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83 and 84, preferably the compound of any one of Embodiments 79, 80, 81, 83 and 84, wherein Xaa5 is a residue of an α-L-amino acid selected from the group consisting of Glu, Gln, Asp, Asn, Ser, Hse, Trp, Lys, Arg, His, Hly, and Har. Embodiment 86. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 and 85, preferably the compound of any one of Embodiments 79, 80, 81, 82, 83, 84 and 85, wherein Xaa5 is a residue of an α-L-amino acid selected from the group consisting of Glu, Gln, Asp, Asn, Ser, and Hse. Embodiment 87. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, preferably the compound of any one of Embodiments 79, 80, 81, 82, 83, 84, 85 and 86, wherein Xaa5 is a Glu residue. Embodiment 88. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 and 78, wherein Xaa5 is a residue of a cyclic α-L-amino acid, preferably Xaa5 is a Pro residue. Embodiment 89. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87 and 88, wherein Xaa6 is a residue of an α-amino acid of formula (VIIa) wherein p is 1 or 0, preferably p is 1, R6a is (C1-C2)alkyl, R6b is methyl, R6c is H if p is 0, and is H or methyl, if p is 1. Embodiment 90. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88 and 89, preferably the compound of Embodiment 89, wherein the stereo configuration of Xaa6 is the L-configuration or is the D-configuration, preferably the stereo configuration of Xaa6 is the D-configuration. Embodiment 91. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 and 90, preferably the compound of any one of Embodiments 89 and 90, wherein Xaa6 is a residue of an α-amino acid selected from the group consisting of leu, Leu, Npg, Val, Ile and Hle. Embodiment 92. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 and 91, preferably the compound of any one of Embodiments 89, 90 and 91, wherein Xaa6 is a residue of an α-amino acid selected from the group consisting of leu, Leu, Npg, Val and Ile. Embodiment 93. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 and 92, preferably the compound of any one of Embodiments 89, 90, 91 and 92, wherein Xaa6 is residue of a leu residue. Embodiment 94. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 and 93, preferably the compound of any one of Embodiments 83 and 90, wherein the stereo configuration of Xaa5 is the L-configuration and the stereo configuration of Xaa6 is theD-configuration, or the stereo configuration of Xaa5 is theD-configuration and the stereo configuration of Xaa6 is the L-configuration, preferably the stereo configuration of Xaa5 is the L-configuration and the stereo configuration of Xaa6 is the D-configuration. Embodiment 95. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94, wherein Xaa8 is a residue of an aliphatic cyclic α-amino acid or a residue of an aliphatic heterocyclic α-amino acid, preferably Xaa8 is a residue of a cyclic α-amino acid of formula (IXa), wherein r is 2 or 1, preferably r is 2, X8 is selected from the group consisting of NR8a, O, NH, and CH2, wherein R8a is a Z group or R8a is acetyl, preferably R8a is a Z group, the Z group is a chelator optionally comprising a linker, wherein more preferably the chelator is DOTA. Embodiment 96. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 95, preferably the compound of Embodiment 95, wherein Xaa8 is a residue of an aliphatic heterocyclic α-amino acid of formula (IXd) wherein X8 is selected from the group consisting of NR8a, O, and NH, wherein R8a is a Z group, wherein preferably the Z group is a chelator optionally comprising a linker, wherein more preferably the Z group is a chelator without an optional linker, wherein most preferably the chelator is DOTA. Embodiment 97. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 and 96, preferably the compound of any one of Embodiments 95 and 96, wherein Xaa8 is a residue of an aliphatic heterocyclic α-amino acid of formula (IXd), wherein X8 is NR8a or O, wherein R8a is a Z group, wherein the Z group is a chelator, wherein preferably the chelator is DOTA. Embodiment 98. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 95, preferably the compound of Embodiment 95, wherein Xaa8 is a residue a cyclic α-amino acid selected from the group consisting of Apc(R8a), Apc, Thp, Egz, and Eca, wherein R8a is a Z group, wherein if the Z group is a chelator optionally comprising a linker, preferably the chelator is DOTA, or R8a is acetyl. Embodiment 99. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 and 98, preferably the compound of any one of Embodiments 95, 96 and 98, wherein Xaa8 is a residue of a cyclic α-amino acid residue selected from the group consisting of Apc(R8a), Apc, and Thp, wherein R8a is a Z group, wherein if the Z group is a chelator optionally comprising a linker, preferably the chelator is DOTA, or R8a is acetyl. Embodiment 100. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99, preferably the compound of any one of Embodiments 95, 96, 97, 98 and 99, wherein Xaa8 is Apc(R8a), wherein R8a is a Z group, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator a) preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. Embodiment 101. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100, preferably the compound of any one of Embodiments 95, 96, 97, 98, 99 and 100, more preferably the compound of Embodiment 100, wherein the chelator is DOTA. Embodiment 102. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94, wherein Xaa8 is an Aic residue. Embodiment 103. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94, wherein Xaa8 is a residue of an α-amino acid selected from the group consisting of Lys, Lys(R8e), lys(R8e), Amk(R8e), Dab(R8e) and dab(R8e), wherein R8e is a Z group, preferably the Z group is a chelator optionally comprising a linker. Embodiment 104. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 103, preferably the compound of Embodiment 103, wherein Xaa8 is a residue of an α-amino acid selected from the group consisting of Lys(R8e), lys(R8e), Amk(R8e), Dab(R8e) and dab(R8e), wherein R8e is a Z group, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator a) preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. Embodiment 105. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 103 and 104, preferably the compound of any one of Embodiments 103 and 104, more preferably the compound of Embodiment 104, wherein Xaa8 is an Amk(R8e) residue, wherein R8e is a Z group, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator a) preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. Embodiment 106. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94, wherein Xaa8 is a residue of an α-amino acid residue selected from the group consisting of Aib, Deg, Ams, ala, Ala, Gln, Thr, Trp, Phe and Glu. Embodiment 107. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 and 106, wherein Xaa9 is a residue of an amino acid of formula (Xa) wherein R9a is selected from the group consisting of (C1-C4)alkyl, COOH, CONH2, OH, NH2, NHC(=NH)NH2, an aryl ring and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indoyl, and cyclo-hexyl, R9b is methyl or H, R9c is H or methyl, and v is 0, 1, 2, preferably v is 1. Embodiment 108. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 and 107, preferably the compound of Embodiment 107, wherein Xaa9 is a residue of an amino acid of formula (Xa), wherein R9a is selected from the group consisting of (C1-C2)alkyl, COOH, OH, NHC(=NH)NH2, an aryl ring and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indoyl, and cyclo-hexyl, R9b is methyl or H, R9c is H, and v is 0, 1, 2, preferably v is 1. Embodiment 109. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 and 107, preferably the compound of Embodiment 107, wherein Xaa9 is a residue of an α-L-amino acid selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe, Ser, Cha, Npg and Tle. Embodiment 110. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108 and 109, preferably the compound of Embodiments 107, 108 and 109, more preferably the compound of Embodiment 109, wherein Xaa9 is a residue of an α-L-amino acid selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe and Ser. Embodiment 111. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109 and 110, preferably the compound of Embodiments 107, 108, 109 and 110, more preferably the compound of Embodiment 110, wherein Xaa9 is a Leu residue. Embodiment 112. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 and 111, wherein Xaa10 is a residue of an amino acid of formula (XIa) wherein R10a is selected from the group consisting of (C -C )alky 10a 1 2 l and phenyl, preferably R is (C1-C2)alkyl, more preferably (C1-C2)alkyl is ethyl, R10b is selected from the group consisting of methyl and H, preferably R10b is methyl, R10c is selected from the group consisting of H and methyl, R10C is H, if w is 1, preferably R10c is H, and w is 0 or 1, preferably w is 0. Embodiment 113. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 and 112, preferably the compound of Embodiment 112, wherein Xaa10 is a residue of an amino acid of formula (XIa), wherein R10a is selected from (C1-C2)alkyl, preferably is ethyl, R10b is selected from the group consisting of methyl and H, preferably R10b is methyl, R10c is selected from the group consisting of H and methyl, R10C is H, if w is 1, preferably R10c is H, and w is 0 or 1, preferably w is 0. Embodiment 114. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 and 112, preferably the compound of Embodiment 112, wherein Xaa10 is a residue of an α-L-amino acid selected from the group consisting of Ile, Leu, Tle, Val, and Phe. Embodiment 115. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113 and 114, preferably the compound of any one of Embodiments 112, 113 and 114, wherein Xaa10 is a residue of an α-L-amino acid selected from the group consisting of Ile, Leu and Tle. Embodiment 116. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 and 115, preferably the compound of any one of Embodiments 112, 113, 114 and 115, wherein Xaa10 is an Ile residue. Embodiment 117. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa1 is Asp, Asn, Glu, Gln or Cya, Xaa2 is Trp, Hyw, 5Fw, 6Clw or 7Fw, Xaa3 is 5Clw, 5Brw, 5Fw, Trp, 1Ni, Bta, 6Fw or Trp, Xaa4 is Tap, Hyp, 4Tfp, Pro, H3p, Eaz, Oxa, Dtc, Nmg, Nleu, Nlys, Nphe or Nglu, Xaa5 is Glu, glu, Nme, Gln, Asp, Asn or Hse, Xaa6 is leu, Leu, Npg, Val or Ile, Xaa7 is Cys or Hcy, Dap Xaa8 is Apc(DOTA), Thp, Apc, Aib, Deg, Ams, Amk(DOTA), Egz, Eca, or ala, Xaa9 is Leu, Hle, Ile, Phe, Glu, Arg, Ser or Trp, Xaa10 is Ile, Leu, Val or Tle, Xaa11 is Cys, Hcy, Dap and Yc is 3MeBn or 3Lut. Embodiment 118. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa1 is Asp or Glu, Xaa2 is Trp or Hyw, Xaa3 is 5Clw or 5Brw, Xaa4 is Tap, Hyp, or Pro, Xaa5 is Glu, Xaa6 is leu or Leu, Xaa7 is Cys, Xaa8 is Apc(DOTA) or Amk(DOTA), Xaa9 is Leu, Xaa10 is Ile Xaa11 is Cys and Yc is 3Lut. Embodiment 119. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa1 is Asp, Xaa2 is Trp, Xaa3 is 5Clw, Xaa4 is Tap or Hyp, Xaa5 is Glu, Xaa6 is leu, Xaa7 is Cys, Xaa8 is Apc(DOTA) or Amk(DOTA), Xaa9 is Leu, Xaa10 is Ile Xaa11 is Cys and Yc is 3Lut. Embodiment 120. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118 and 119, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-I), wherein comprises a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety, a1 is 0, 1, 2, 3, 4, 5, or 6, if XA is a triazolyl moiety, preferably a1is 2, if XA is selected from the group comprising a nitrogen atom, a hydroxymethyl- triazolyl moiety and an urea moiety, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3is 0 or 1, and b2is 0 or 1, and wherein RA2 is absent, if XA is selected from the group comprising a triazolyl moiety, a hydroxmethyl-triazolyl moiety and an urea moiety, or RA2 is H or a first level alkyl group of a structure of formula (A-II), if XA is a nitrogen atom, wherein a2 is 0 or 1, b1is 0 or 1, wherein if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III) or RA3 and RA4 are H, or wherein if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein in formula (A-III) a3 is 0 or 1, and b2 is 0 or 1, and wherein the carbonyl group of the structure (A-I) is covalently attached to the α-nitrogen atom of Xaa1, or if a linker comprising an amino group and a carbonyl group, is interspersed between the bio- distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the structure (A-I) is covalently attached to the amino group of the linker. Embodiment 121. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably the compound of Embodiment 120, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom is covalently attached, wherein to the nitrogen atom (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-IV), wherein is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1 is 0 or 1, wherein, if b1 is 0, RA3 and RA4 are individually and independently second level alkyl groups of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is H, wherein a3 is 0 or 1, and b2is 0 or 1, and wherein RA2 is H or a first level alkyl group of a structure of formula (A-II), a2is 0 or 1, b1 is 0 or 1, wherein if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), wherein in formula (A-III) a3is 0 or 1, and b2 is 0 or 1, or RA3 and RA4 are each H, or wherein if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is H, wherein in formula (A-III) a3 is 0 or 1, and b2is 0 or 1. Embodiment 122. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 121, preferably the compound of any one of Embodiments 120 and 121, more preferably the compound of Embodiment 121, wherein the bio-distribution modifier comprised by the N-terminal modification group A comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom is covalently attached, wherein to the nitrogen atom 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises two hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein preferably the bio-distribution modifier is a structure of formula (A-VII), wherein a1is 0, 1, 2, 3, 4, 5, or 6, preferably a1is 4, RA1 is a first level alkyl group of a structure of formula (A-V), wherein a2is 0 or 1 and b1is 0 or 1, and wherein RA2 is a first level alkyl group of a structure of formula (A-V), wherein a2 is 0 or 1 and b1is 0 or 1, or RA2 is H. Embodiment 123. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 and 122, preferably the compound of any one of Embodiment 120, 121 and to 122, more preferably the compound of Embodiment 122, wherein RA1 is a first level alkyl group of structure of formula (A-V), wherein a2is 0 or 1, preferably a2is 0, and b1is 0 or 1, and wherein RA2 is H. Embodiment 124. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 and 123, preferably the compound of any one of Embodiments 120, 121, 122 and to 123, more preferably the compound of Embodiment 123, wherein the bio-distribution modifier comprised by the N-terminal modification group A is HAC:Ahx. Embodiment 125. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 and 122, preferably the compound of any one of Embodiments 120, 121 and 122, more preferably the compound of Embodiment 122, wherein RA1 is a first level alkyl group of a structure of formula (A-V), wherein a2is 0 or 1, preferably a2is 1, and b1is 0 or 1, and wherein RA2 is a first level alkyl group of structure of formula (A-V), wherein a2is 0 or 1, preferably a2is 1, and b1is 0 or 1. Embodiment 126. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 and 125, preferably the compound of any one of Embodiments 120 to 122 and 125, more preferably the compound of Embodiments 125, wherein RA1 is a first level alkyl group of structure of formula (A-V), wherein a2is 0 or 1, preferably a2is 1, and b1is 0 or 1, and wherein RA2 is a first level alkyl group of structure of formula (A-V), wherein a2 is 0 or 1, preferably a2 is 1, and b1 is 0 or 1 and wherein a A1 A2 A1 A2 1 in R and a1 in R are identical and b1 in R and b1 in R are identical. Embodiment 127. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 125 and 126, preferably the compound of any one of Embodiments 120, 121 and 122, 125 and 126, more preferably the compound of Embodiment 126, wherein the bio-distribution modifier comprised by the N- terminal modification group A is selected from the group comprising HPD2:Ahx, PEO2:Ahx. Embodiment 128. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 121, preferably the compound of any one of Embodiment 120 and 121, more preferably the compound of Embodiment 121, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom is covalently attached, wherein to the nitrogen atom 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-IV), wherein a1is 0, 1, 2, 3, 4, 5, or 6, preferably a1is 4, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3 is 0 or 1, and b2is 0 or 1, preferably b1is 0, and wherein RA2 is H or a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1 is 0 or 1, wherein if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), wherein in formula (A-III) a3is 0 or 1, and b2 is 0 or 1, or wherein if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein in formula (A-III) a3 is 0 or 1, and b2is 0 or 1, preferably b1is 0. Embodiment 129. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 and 128, preferably the compound of any one of Embodiments 120, 121 and 128, more preferably the compound of Embodiment 128, wherein the bio-distribution modifier comprised by the N-terminal modification group A is a structure of formula (A-IV), wherein a1 is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-VI), wherein a2is 0 or 1, and wherein RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-VII), wherein a3 is 0 or 1, and wherein RA2 is a first level alkyl group of a structure of formula (A-VI), wherein a2is 0 and wherein, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-VII), wherein in formula (A-VII) a3is 0 or 1, or RA2 is H. Embodiment 130. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 128 and 129, preferably the compound of any one of Embodiments 120, 121, 128 and 129, more preferably the compound of Embodiment 129, wherein RA1 is a first level alkyl group of structure of formula (A-VI), wherein a2is 0 or 1, preferably a2is 0, and wherein a3in RA3 and a3in RA4 are identical and wherein RA2 is H. Embodiment 131. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 128, 129 and 130, preferably the compound of any one of Embodiments 120, 121, 128, 129 and 130, more preferably the compound of Embodiment 130, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC2:HAC:Ahx and HPD2:HAC:Ahx. Embodiment 132. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 and 128, preferably the compound of any one of Embodiments 120, 121 and 128, more preferably the compound of Embodiment 128, wherein RA1 is a first level alkyl group of a structure of formula (A-VI), wherein a2is 0 or 1, preferably a2is 1, and wherein RA2 is a first level alkyl group of a structure of formula (A-VI), wherein a2 is 0 or 1, preferably a2 is 1, preferably a in RA1 and A2 2 a2 in R are identical, and wherein preferably a in RA3 of A1 3 R , and a in A4 A1, 3 R of R and a3in RA3 of RA2 and a A 3 in R 4 of RA2 are identical. Embodiment 133. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 128 and 132, preferably the compound of any one of Embodiments 120, 121, 128 and 132, more preferably the compound of Embodiment 132, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC4:HPD2:Ahx, HPD4:HPD2:Ahx. Embodiment 134. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably the compound of any one of Embodiment 120, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a triazolyl moiety is covalently attached, wherein to the triazolyl moiety (a) one first level alkyl groups is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) one first level alkyl groups is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-VIII), wherein a1 is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 2, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3 is 0 or 1, and b2 is 0 or 1. Embodiment 135. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 134, preferably the compound of any one of Embodiments 120 and 134, more preferably the compound of Embodiment 134, wherein to the triazolyl moiety one first level alkyl groups is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein preferably the bio-distribution modifier is a structure of formula (A-VIII), wherein a1is 0, 1, 2, 3, 4, 5, or 6, preferably a1is 2, RA1 is a first level alkyl group of a structure of formula (A-V), wherein a2 is 0 or 1 and b1 is 0 or 1. Embodiment 136. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134 and 135, preferably the compound of any one of Embodiments 120, 134 and 135, more preferably the compound of Embodiment 135, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HPD:Hyx, PEO:Hyx, TRIS:Hyx and HAC:Hyx, preferably is selected from the group comprising HPD:Hyx, PEO:Hyx and TRIS:Hyx. Embodiment 137. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 134, preferably the compound of any one of Embodiments 120 and 134, more preferably the compound of Embodiment 134, wherein to the triazolyl moiety one first level alkyl groups is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-VIII), wherein a1 is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 2, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2 is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula wherein a3 is 0 or 1. Embodiment 138. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134 and 137, preferably the compound of any one of Embodiments 120, 134 and 137, more preferably the compound of Embodiment 137, wherein if b1is 0, a3in RA3 and a3in RA4 are identical and b1in RA3 and b1in RA4 are identical. Embodiment 139. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134, 137 and 138, preferably the compound of any one of Embodiments 120, 134, 137 and 138, more preferably the compound of Embodiment 138, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC2:HPD:Hyx, HPD2:HPD:Hyx, HAC2:HAC:Hyx, HPD2:HAC:Hyx, preferably comprising HAC2:HPD:Hyx and HPD2:HPD:Hyx . Embodiment 140. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134 and 137, preferably the compound of any one of Embodiments 120, 134 and 137, more preferably the compound of Embodiment 137, wherein b1 is 1 and each and any of RA3, RA4 and RA5 is a second level alkyl group of a structure of formula (A-VII), wherein a in RA3, A4 A5 3 a3 in R and a3 in R are identical. Embodiment 141. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134, 137 and 140, preferably the compound of any one of Embodiments 120, 134, 137 and 140, more preferably the compound of Embodiment 140, wherein the bio-distribution modifier comprises by the N-terminal modification group A is selected from the group comprising HAC3:TRIS:Hyx, HPD3:PEO:Hyx, HPD3:TRIS:Hyx, and HAC3:PEO:Hyx . Embodiment 142. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134 and 137, preferably the compound of any one of Embodiments 120, 134 and 137, more preferably the compound of Embodiment 137, wherein b1is 1 and RA3 and RA4 are a second level alkyl group of a structure of formula (A-VII) and RA5 is H, wherein a3in RA3 and a3in RA4 are identical. Embodiment 143. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134, 137 and 142, preferably the compound of any one of Embodiments 120, 134, 137 and 142, more preferably the compound of Embodiment 142, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HPD2:PEO:Hyx, HAC2:PEO:Hyx, HPD2:TRIS:Hyx and HAC2:TRIS:Hyx. Embodiment 144. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134 and 137, preferably the compound of any one of Embodiments 120, 134 and 137, more preferably the compound of Embodiment 137, wherein b1is 1 and RA3 is a second level alkyl group of a structure of formula (A-III) and RA4 and RA5 are each H. Embodiment 145. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 134, 137 and 144, preferably the compound of any one of Embodiments 120, 134, 137 and 144, more preferably the compound of Embodiment 144, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HPD:PEO:Hyx, HAC:PEO:Hyx, HPD:TRIS:Hyx and HAC:TRIS:Hyx. Embodiment 146. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably the compound of Embodiment 120, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid, a hydroxymethyl-triazolyl moiety is covalently attached, wherein to the hydroxymethyl triazolyl moiety one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to two second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-IX), wherein is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-VI), wherein a2 is 0 or 1, and RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula wherein a3 is 0 or 1. Embodiment 147. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 146, preferably the compound of any one of Embodiments 120 and 146, more preferably the compound of Embodiment 146, wherein a3in RA3 and a3in RA4 are identical. Embodiment 148. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 146 and 147, preferably the compound of any one of Embodiments 120, 146 and 147, more preferably the compound of Embodiment 147, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC2:HAC:Tzx, HAC2:HPD:Tzx, HPD2:HPD:Tzx, HPD2:HAC:Tzx. Embodiment 149. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably the compound of Embodiment 120, wherein a linker comprising an amino group and an carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid an urea moiety is covalently attached, wherein to the urea moiety (a) one first level alkyl group is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-X), wherein a1is 0, 1, 2, 3, 4, 5, or 6, preferably a1is 4, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2is 0 or 1, b1is 0 or 1, wherein, if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3 is 0 or 1, and b2 is 0 or 1, and wherein the carbonyl group of the structure (A-X) is covalently attached to the α-nitrogen atom of Xaa1, or if a linker comprising an amino group and a carbonyl group is interspersed between the bio- distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the structure (A-X) is covalently attached to the amino group of the linker. Embodiment 150. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 149, preferably the compound of any one of Embodiments 120 and 149, more preferably the compound of Embodiment 149, wherein to the urea moiety one first level alkyl groups is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein preferably the bio-distribution modifier is a structure of formula (A-X), wherein is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-V), wherein a2is 0 or 1 and b1is 0 or 1. Embodiment 151. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149 and 150, preferably the compound of any one of Embodiments 120, 149 and 150, more preferably the compound of Embodiment 150, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HPD:Aur, PEO:Aur, TRIS:Aur and HAC:Aur, preferably is selected from the group comprising PEO:Aur and TRIS:Aur. Embodiment 152. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 149, preferably the compound of any one of Embodiments 120 and 149, more preferably the compound of Embodiment 149, wherein to the urea moiety one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-X), wherein a1 is 0, 1, 2, 3, 4, 5, or 6, preferably a1 is 2, RA1 is a first level alkyl group of a structure of formula (A-II), wherein a2 is 0 or 1, b1 is 0 or 1, wherein, if b1is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or wherein, if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), wherein a3 is 0 or 1. Embodiment 153. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149 and 152, preferably the compound of any one of Embodiments 120, 149 and 152, more preferably the compound of Embodiment 152, wherein if b1 is 0, a3 in RA3 and a3 in RA4 are identical. Embodiment 154. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149, 152 and 153, preferably the compound of any one of Embodiments 120, 149, 152 and 153, more preferably the compound of Embodiment 153, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC2:HPD:Aur, HPD2:HPD:Aur, HAC2:HAC:Aur, HPD2:HAC:Aur, preferably is selected from the group comprising HAC2:HAC:Aur and HPD2:HAC:Aur. Embodiment 155. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149 and 152, preferably the compound of any one of Embodiments 120, 149 and 152, more preferably the compound of Embodiment 152, wherein b1is 1 and each and any of RA3, RA4 and RA5 is a second level alkyl group of a structure of formula (A-III), wherein a3 in RA3, a3 in RA4 and a3 in RA5 are identical. Embodiment 156. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149, 152 and 155, preferably the compound of any one of Embodiments 120, 149, 152 and 155, more preferably the compound of Embodiment 155, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur. Embodiment 157. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149 and 152, preferably the compound of any one of Embodiments 120, 149 and 152, more preferably the compound of Embodiment 152, wherein b A3 A4 1 is 1 and R and R are a second level alkyl group of a structure of formula (A-VII) and RA5 is H, wherein a i A3 A4 3 n R and a3 in R are identical. Embodiment 158. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149, 152 and 157, preferably the compound of any one of Embodiments 120, 149, 152 and 157, more preferably the compound of Embodiment 157, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC2:PEO:Aur, HAC2:TRIS:Aur, HPD2:PEO:Aur and HPD2:TRIS:Aur. Embodiment 159. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149 and 152, preferably the compound of any one of Embodiments 120, 149 and 152, more preferably the compound of Embodiment 152, wherein b A3 1 is 1 and R is a second level alkyl group of a structure of formula (A-III) and RA4 and RA5 are H. Embodiment 160. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 149, 152 and 159, preferably the compound of any one of Embodiments 120, 149, 152 and 159, more preferably the compound of Embodiment 159, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HAC:PEO:Aur, HAC:TRIS:Aur, HPD:PEO:Aur and HPD:TRIS:Aur. Embodiment 161. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159 and 160, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety or an urea moiety is covalently attached, wherein to the nitrogen atom, to the triazolyl moiety, to the hydroxymethyl triazolyl moiety or to the urea moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-I), wherein XC comprises a nitro gen atom, a triazolyl moiety, a hydroxymethyl-triazolyl moiety and an urea moiety, a4 is 0, 1, 2, 3, or 4, if XC is a triazolyl moiety, preferably a4is 1 or 2, more preferably a4is 1, if XC is selected from the group comprising a nitrogen atom, a hydroxymethyl- triazolyl moiety and an urea moiety, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5is 0 or 1, b3 is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are H, or wherein, if b is 1, each an C3 C4 C5 3 d any of R , R and R is selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein a6 is 0 or 1, and b4is 0 or 1 and RC2 is absent, if XC is selected from the group comprising a triazolyl moiety, a hydroxmethyl-triazolyl moiety and an urea moiety, or RC2 is H or is a first level alkyl group of a structure of formula (C-II), if XC is a nitrogen atom, wherein a5 is 0 or 1, b3is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are H, or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein in formula (C-III) a6 is 0 or 1, and b4is 0 or 1, and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising an amino group and a carbonyl group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably the linker is interspersed between Xaa11 and the bio-distribution comprised by the C-terminal modification group C-term. Embodiment 162. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160 and 161, preferably the compound of Embodiment 161, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom is covalently attached, wherein to the nitrogen atom, (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-IV), wherein a4is 0, 1, 2, 3, or 4, preferably a4is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5is 0 or 1, b3is 0 or 1, wherein, if b3 is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are each H, or wherein, if b is 1, each and any of C3 C4 C5 3 R , R and R is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein a6is 0 or 1, and b4is 0 or 1 and wherein RC2 is H or is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3 is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are H, or wherein, if b3 is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein in formula (C-III) a6 is 0 or 1, and b4is 0 or 1, and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising an amino group and a carbonyl group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably the linker is interspersed between Xaa11 and the bio- distribution comprised by the C-terminal modification group C-term, preferably the linker is selected from the group comprising APAc and Ttds. Embodiment 163. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 162, preferably the compound of any one of Embodiments 161 and 162, more preferably the compound of Embodiment 162, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom is covalently attached, wherein to the nitrogen atom, 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein preferably the bio-distribution modifier is a structure of formula (C-IV), wherein a4 is 0, 1, 2, 3, or 4, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-V), wherein a5is 0 or 1 and b3is 0 or 1, and wherein RC2 is a first level alkyl group of a structure of formula (C-V), wherein a5 is 0 or 1 and b3 is 0 or 1, or RA2 is H. Embodiment 164. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 163, preferably the compound of any one of Embodiments 161, 162 and 163, more preferably the compound of Embodiment, wherein RC1 is a first level alkyl group of structure of formula (C-V), wherein a is 0 or 1 C2 5 , preferably a5 is 0, and b3 is 0, and wherein R is H. Embodiment 165. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163 and 164, preferably the compound of any one of Embodiment 161, 162, 163 and 164, more preferably the compound of Embodiment 164, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is lys:HAC. Embodiment 166. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 163, preferably the compound of any one of Embodiments 161, 162 and 163, more preferably the compound of Embodiment 163, wherein RC1 is a first level alkyl group of a structure of formula (C-V), wherein a is 0 or 1, preferably a i C2 5 5 s 1, and b3 is 0 or 1, and wherein R is a first level alkyl group of structure of formula (C-V), wherein a5is 0 or 1, preferably a5is 1, and b3is 0 or 1. Embodiment 167. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163 and 166, preferably the compound of any one of Embodiments 161, 162 and 163 and 166, more preferably the compound of Embodiment 166, wherein RC1 is a first level alkyl group of structure of formula (C-V), wherein a5is 0 or 1, preferably a5is 1, and b3is 0 or 1, and wherein RC2 is a first level alkyl group of structure of formula (C-V), wherein a5 is 0 or 1, preferably a5 is 1, and b3 is 0 or 1, and wherein a C 5 in R 1 and a5 in RC2 are identical, and b3in RC1 and b3in RC2 are identical. Embodiment 168. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166 and 167, preferably the compound of any one of Embodiments 161, 162 and 163, 166 and 167, more preferably the compound of Embodiment 167, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term is selected from the group comprising lys:HPD2 and lys:PEO2. Embodiment 169. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 162, preferably the compound of any one of Embodiments 161 and 162, more preferably the compound of Embodiment 162, wherein a linker is optionally interspersed between Xaa11 and the bio- distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom is covalently attached, wherein to the nitrogen atom, 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-IV), wherein a4 is 0, 1, 2, 3, or 4, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3 is 0 or 1, wherein, if b3 is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are each H, or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is a second level alkyl group of a structure of formula (C-III), wherein a6is 0 or 1, and b4is 0 or 1, preferably b4is 0 and wherein RC2 is H or is a first level alkyl group of a structure of formula (C-II), wherein a5is 0 or 1, b3 is 0 or 1, wherein, if b3 is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are each H, or wherein, if b3 is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein in formula (C-III) a6 is 0 or 1, and b4 is 0 or 1. Embodiment 170. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 169, preferably the compound of any one of Embodiments 161, 162 and 169, more preferably the compound of Embodiment 169, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is a structure of formula (C-IV), wherein a4 is 0, 1, 2, 3, 4, 5, or 6, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-VI), wherein a5is 0 or 1, and wherein RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-VII), wherein a6 is 0 or 1, and wherein RC2 is a first level alkyl group of a structure of formula (C-VI), wherein a5is 0 and wherein, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-VII), wherein in formula (C-VII) a6is 0 or 1, or RC2 is H. Embodiment 171. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 169 and 170, preferably the compound of any one of Embodiments 161, 162, 169 and 170, more preferably the compound of Embodiment 170, wherein RC1 is a first level alkyl group of structure of formula (C-VI), wherein a is 0 or 1, preferably a is 0, and wh C3 C4 5 5 erein a6 in R and a6 in R are identical and wherein RC2 is H. Embodiment 172. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 169 to 171, preferably the compound of any one of Embodiments 161, 162 and 169 to 171, more preferably the compound of Embodiment 171, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising lys:HAC:HAC2 and lys:HAC:HPD2. Embodiment 173. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162 and 169, preferably the compound of any one of Embodiments 161, 162 and 169, more preferably the compound of Embodiment 169, wherein wherein RC1 is a first level alkyl group of a structure of formula (C-VI), wherein a5 is 0 or 1, preferably a5 is 1, and wherein RC2 is a first level alkyl group of a structure of formula (C-VI), wherein a5is 0 or 1, preferably a5is 1, preferably a in RC1 and a in C2 5 5 R are identical, and wherein preferably a C3 C4 C1 C3 C4 C2 6 in R and a6 in R of R and a6 in R and a6 in R of R are identical. Embodiment 174. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 169 and 173, preferably the compound of any one of Embodiments 161, 162, 169 and 173, more preferably the compound of Embodiment 173, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising lys:HPD2:HAC4 and lys:HPD2:HPD4. Embodiment 175. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160 and 161, preferably the compound of Embodiment 161, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a triazolyl moiety is covalently attached, wherein to the triazolyl moiety, (a) one first level alkyl group is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) one first level alkyl groups is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-VIII), wherein a4is 0, 1, 2, 3, or 4, more preferably a4is 1 RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5is 0 or 1, b3 is 0 or 1, wherein, if b3 is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are each H, or wherein, if b C3 C4 C5 3 is 1, each and any of R , R and R is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein a6 is 0 or 1, and b4 is 0 or 1. Embodiment 176. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 175, preferably the compound of any one of Embodiments 161 and 175, more preferably the compound of Embodiment 175, wherein to the triazolyl moiety one first level alkyl groups is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein the preferably the bio-distribution modifier is a structure of formula (C-VIII), wherein a4is 0, 1, 2, 3, or 4, more preferably a4is 1 RC1 is a first level alkyl group of a structure of formula (C-V), wherein a5is 0 or 1 and b3is 0 or 1. Embodiment 177. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 161, 175 and 176, preferably the compound of any one of Embodiments 161, 175 and 176, more preferably the compound of Embodiment 176, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term is selected from the group comprising prx:HPD, prx:PEO, prx:TRIS and prx:HAC, preferably is selected from the group comprising prx:HPD, prx:PEO and prx:TRIS. Embodiment 178. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 175, preferably the compound of any one of Embodiments 161 and 175, more preferably the compound of Embodiment 175, wherein to the triazolyl moiety one first level alkyl groups is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (C-VIII), wherein a4 is 0, 1, 2, 3, or 4, more preferably a4 is 1 RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-VII) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-VII), wherein a6is 0 or 1. Embodiment 179. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175 and 178, preferably the compound of any one of Embodiments 161, 175 and 178, more preferably the compound of Embodiment 178, wherein if b C3 C4 3 is 0, and a6 in R and a6 in R are identical. Embodiment 180. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175, 178 and 179, preferably the compound of any one of Embodiments 161, 175, 178 and 179, more preferably the compound of Embodiment 179, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising prx:HPD:HAC2, prx:HPD:HPD2, prx:HAC:HAC2 and prx:HAC:HPD2, preferably is selected from the group comprising prx:HPD:HAC2 and prx:HPD:HPD2. Embodiment 181. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175 and 178, preferably the compound of any one of Embodiments 161, 175 and 178, more preferably the compound of Embodiment 178, wherein if b3is 1 and each and any of RC3, RC4 and RC5 is a second level alkyl group of a structure of formula (C-VII), wherein a C3 C4 C5 6 in R , a6 in R and a6 in R are identical. Embodiment 182. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175, 178 and 181, preferably the compound of any one of Embodiments 161, 175, 178 and 181, more preferably the compound of Embodiment 181, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising prx:PEO:HPD3, prx:TRIS:HPD3, prx:TRIS:HAC3 and prx:PEO:HAC3. Embodiment 183. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 161, 175 and 178, preferably the compound of any one of Embodiments 161, 175 and 178, more preferably the compound of Embodiment 178, wherein if b3is 1 and RC3 and RC4 are a second level alkyl group of a structure of formula (C-VII) and RC5 is H, and a in RC3 and a i C4 6 6 n R are identical. Embodiment 184. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175, 178 and 183, preferably the compound of any one of Embodiments 161, 175, 178 and 183, more preferably the compound of Embodiment 183, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising prx:PEO:HPD2, prx:PEO:HAC2, prx:TRIS:HPD2 and prx:TRIS:HAC2. Embodiment 185. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175 and 178, preferably the compound of any one of Embodiments 161, 175 and 178, more preferably the compound of Embodiment 178, wherein if b C3 3 is 1 and R is a second level alkyl group of a structure of formula (C-VII), RC4 and RC5 are each H. Embodiment 186. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 175, 178 and 185, preferably the compound of any one of Embodiment 161, 175, 178 and 185, more preferably the compound of Embodiment 185, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising prx:PEO:HPD, prx:PEO:HAC, prx:TRIS:HPD and prx:TRIS:HAC. Embodiment 187. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, preferably the compound of Embodiment 161, wherein a linker optionally comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a hydroxymethyl-triazolyl moiety is covalently attached, wherein to the hydroxymethyl triazolyl moiety one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to two second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-IX), wherein a4 is 0, 1, 2, 3, or 4, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-VI), wherein a5is 0 or 1, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-VII), wherein a6is 0 or 1. Embodiment 188. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 187, preferably the compound of any one of Embodiments 161 and 187, more preferably the compound of Embodiment 187, wherein a in RC3 and a i C4 6 6 n R are identical. Embodiment 189. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 187 and 188, preferably the compound of any one of Embodiments 161, 187 and 188, more preferably the compound of Embodiment 188, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising tzk:HAC:HAC2, tzk:HPD:HAC2, tzk:HPD:HPD2, and tzk:HAC:HPD2. Embodiment 190. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160 and 161, preferably the compound of Embodiment 161, wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid an urea moiety is covalently attached, wherein to the urea moiety (a) one first level alkyl group is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-X), wherein a4 is 0, 1, 2, 3, or 4, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3 is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III), or RC3 and RC4 are H, or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), wherein a6 is 0 or 1, and b4 is 0 or 1 and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising an amino group and a carbonyl group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably the linker is interspersed between Xaa11 and the bio-distribution comprised by the C-terminal modification group C-term. Embodiment 191. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 190, preferably the compound of any one of Embodiments 161 and 190, more preferably the compound of Embodiment 190, wherein to the urea moiety one first level alkyl group is covalently attached, wherein the first level alkyl group comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, wherein the preferably the bio-distribution modifier is a structure of formula (C-X), wherein a4 is 0, 1, 2, 3, or 4, preferably a4 is 3, RC1 is a first level alkyl group of a structure of formula (C-V), wherein a5 is 0 or 1 and b3 is 0 or 1. Embodiment 192. The compound of any one of Embodiments 1 to 161, 190 and 191, preferably the compound of any one of Embodiments 161, 190 and 191, more preferably the compound of Embodiment 191, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising kur:HPD, kur:PEO, kur:TRIS and kur:HAC. Embodiment 193. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 and 190, preferably the compound of any one of Embodiments 161 and 190, more preferably the compound of Embodiment 190, wherein to the urea moiety one first level alkyl group is covalently attached, wherein the first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein the first level alkyl group comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (C-X), wherein a4is 0, 1, 2, 3, or 4, preferably a4is 3, RC1 is a first level alkyl group of a structure of formula (C-II), wherein a5 is 0 or 1, b3is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-VII), or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is individually and independently selected from a second level alkyl group of a structure of formula (C-VII) and H, preferably each and any of RC3, RC4 and RC5 individually and independently is a second level alkyl group of a structure of formula (C-VII), wherein a6is 0 or 1. Embodiment 194. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190 and 193, preferably the compound of any one of Embodiments 161, 190 and 193, more preferably the compound of Embodiment 193, wherein if b3is 0, a6in RC3 and a6in RC4 are identical. Embodiment 195. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190, 193 and 194, preferably the compound of any one of Embodiments 161, 190, 193 and 194, more preferably the compound of Embodiment 194, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising kur:HPD:HAC2, kur:HPD:HPD2, kur:HAC:HAC2, and kur:HAC:HPD2, preferably is selected from the group comprising kur:HAC:HAC2 and kur:HAC:HPD2. Embodiment 196. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190 and 193, preferably the compound of any one of Embodiments 161, 190 and 193, more preferably the compound of Embodiment 193, wherein if b C3 C4 C5 3 is 1 and each and any of R , R and R is a second level alkyl group of a structure of formula (C-VII) and a6in RC3, a6in RC4 and a6in RC5 are identical. Embodiment 197. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190, 193 and 196, preferably the compound of any one of Embodiments 161, 190, 193 and 196, more preferably the compound of Embodiment 196, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3 and kur:TRIS:HPD3. Embodiment 198. The compound of any one of Embodiments 1 to 161, 190 and 193, preferably the compound of any one of Embodiments 161, 190 and 193, more preferably the compound of Embodiment 193, wherein if b3is 1 and RC3 and RC4 are a second level alkyl group of a structure of formula (C-VII) and RC5 is H, and a in C3 C4 6 R and a6 in R are identical. Embodiment 199. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190, 193 and 198, preferably the compound of any one of Embodiments 161, 190, 193 and 198, more preferably the compound of Embodiment 198, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising kur:PEO:HAC2, kur:TRIS:HAC2, kur:PEO:HPD2 and kur:TRIS:HPD2. Embodiment 200. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190 and 193, preferably the compound of any one of Embodiments 161, 190 and 193, more preferably the compound of Embodiment 193, wherein b i C3 3 s 1 and R is a second level alkyl group of a structure of formula (C-VII) and RC4 and RC5 are each H. Embodiment 201. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 190, 193 and 200, preferably the compound of any one of Embodiments 161, 190, 193 and 200, more preferably the compound of Embodiment 200, wherein the bio-distribution modifier comprised by the C- terminal modification group C-term is selected from the group comprising kur:PEO:HAC, kur:TRIS:HAC, kur:PEO:HPD and kur:TRIS:HPD. Embodiment 202. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201, wherein the bio-distribution modifier comprised by the N-terminal modification group A is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur, TRIS:Aur, HAC2:HPD:Aur, HAC2:HPD:Hyx, HAC4:HPD2:Ahx, HPD2:HPD:Aur, HPD2:HPD:Hyx, HPD4:HPD2:Ahx, HAC2:HAC:Aur, HPD2:HAC:Aur, HAC2:HAC:Ahx, HAC2:HAC:Tzx, HAC2:HPD:Tzx, HPD:Aur, HPD:Hyx, HPD2:HAC:Ahx, HPD2:HPD:Tzx, HAC:Aur, HAC2:PEO:Hyx, HPD2:TRIS:Hyx, HAC2:TRIS:Hyx, HAC2:PEO:Aur, HAC2:TRIS:Aur, HPD2:PEO:Aur, HPD2:TRIS:Aur, HPD2:HAC:Tzx, HPD2:PEO:Hyx, HAC2:HAC:Hyx, HPD2:HAC:Hyx, HPD:PEO:Hyx, HAC:PEO:Hyx, HPD:TRIS:Hyx, HAC:TRIS:Hyx, HAC:PEO:Aur, HAC:TRIS:Aur, HPD:PEO:Aur, HPD:TRIS:Aur, HAC:Ahx and HAC:Hyx, preferably is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur, TRIS:Aur, HAC2:HPD:Aur, HAC2:HPD:Hyx, HAC4:HPD2:Ahx, HPD2:HPD:Aur, HPD2:HPD:Hyx, HPD4:HPD2:Ahx, HAC2:HAC:Aur, HPD2:HAC:Aur, HAC2:HAC:Ahx, HAC2:HAC:Tzx, HAC2:HPD:Tzx, HPD:Aur, HPD:Hyx, HPD2:HAC:Ahx, HPD2:HPD:Tzx, HAC:Aur, HAC2:PEO:Hyx, HPD2:TRIS:Hyx, HAC2:TRIS:Hyx, HAC2:PEO:Aur, HAC2:TRIS:Aur, HPD2:PEO:Aur, HPD2:TRIS:Aur and HPD2:HAC:Tzx, more preferably is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur, TRIS:Aur, HAC2:HPD:Aur, HAC2:HPD:Hyx, HAC4:HPD2:Ahx, HPD2:HPD:Aur, HPD2:HPD:Hyx, HPD4:HPD2:Ahx, HAC2:HAC:Aur and HPD2:HAC:Aur, and most preferably is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur and TRIS:Aur. Embodiment 203. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201 and 202, preferably the compound of Embodiment 202, wherein the bio-distribution modifier comprised by the N-terminal modification group is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur, TRIS:Aur, HAC2:HPD:Aur, HAC2:HPD:Hyx, HAC4:HPD2:Ahx, HPD2:HPD:Aur, HPD2:HPD:Hyx, HPD4:HPD2:Ahx, HAC2:HAC:Aur and HPD2:HAC:Aur and preferably is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur and TRIS:Aur. Embodiment 204. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202 and 203, preferably the compound of any one of Embodiments 202 and 203, more preferably the compound of Embodiment 203, wherein the bio-distribution modifier comprised by the N- terminal modification group is selected from the group comprising HPD2:Ahx, HPD3:PEO:Hyx, PEO:Aur, PEO:Hyx, PEO2:Ahx, TRIS:Hyx, HPD3:TRIS:Hyx, HAC3:TRIS:Hyx, HAC3:PEO:Hyx, HAC3:PEO:Aur, HAC3:TRIS:Aur, HPD3:PEO:Aur, HPD3:TRIS:Aur and TRIS:Aur. Embodiment 205. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203 and 204, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3, kur:TRIS, kur:HPD:HAC2, prx:HPD:HAC2, lys:HPD2:HAC4, kur:HPD:HPD2, prx:HPD:HPD2, lys:HPD2:HPD4, kur:HAC:HAC2, kur:HAC:HPD2, lys:HAC:HAC2, tzk:HAC:HAC2, tzk:HPD:HAC2, kur:HPD, prx:HPD, lys:HAC:HPD2, tzk:HPD:HPD2, kur:HAC, prx:PEO:HAC2, prx:TRIS:HPD2, prx:TRIS:HAC2, kur:PEO:HAC2, kur:TRIS:HAC2, kur:PEO:HPD2, kur:TRIS:HPD2, tzk:HAC:HPD2, prx:PEO:HPD2, prx:HAC:HAC2, prx:HAC:HPD2, prx:PEO:HPD, prx:PEO:HAC, prx:TRIS:HPD, prx:TRIS:HAC, kur:PEO:HAC, kur:TRIS:HAC, kur:PEO:HPD, kur:TRIS:HPD, lys:HAC and prx:HAC, preferably is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3, kur:TRIS, kur:HPD:HAC2, prx:HPD:HAC2, lys:HPD2:HAC4, kur:HPD:HPD2, prx:HPD:HPD2, lys:HPD2:HPD4, kur:HAC:HAC2, kur:HAC:HPD2, lys:HAC:HAC2, tzk:HAC:HAC2, tzk:HPD:HAC2, kur:HPD, prx:HPD, lys:HAC:HPD2, tzk:HPD:HPD2, kur:HAC, prx:PEO:HAC2, prx:TRIS:HPD2, prx:TRIS:HAC2, kur:PEO:HAC2, kur:TRIS:HAC2, kur:PEO:HPD2, kur:TRIS:HPD2 and tzk:HAC:HPD2, more preferably is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3, kur:TRIS, kur:HPD:HAC2, prx:HPD:HAC2, lys:HPD2:HAC4, kur:HPD:HPD2, prx:HPD:HPD2, lys:HPD2:HPD4, kur:HAC:HAC2 and kur:HAC:HPD2, and most preferably is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3 and kur:TRIS. Embodiment 206. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204 and 205, preferably the compound of Embodiment 205, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3, kur:TRIS, kur:HPD:HAC2, prx:HPD:HAC2, lys:HPD2:HAC4, kur:HPD:HPD2, prx:HPD:HPD2, lys:HPD2:HPD4, kur:HAC:HAC2 and kur:HAC:HPD2, and preferably is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3 and kur:TRIS. Embodiment 207. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205 and 206, preferably the compound of any one of Embodiments 205 and 206, more preferably the compound of Embodiment 206, wherein the bio-distribution modifier comprised by the C-terminal modification group C-term is selected from the group comprising lys:HPD2, prx:PEO:HPD3, kur:PEO, prx:PEO, lys:PEO2, prx:TRIS, prx:TRIS:HPD3, prx:TRIS:HAC3, prx:PEO:HAC3, kur:PEO:HAC3, kur:TRIS:HAC3, kur:PEO:HPD3, kur:TRIS:HPD3 and kur:TRIS. Embodiment 208. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 127, 133, 136, 139, 141, 151, 154, 156, 168, 174, 177, 180, 182, 192, 195 and 197, preferably the compound of any one of Embodiment 127, 133, 136, 139, 141, 151, 154, 156, 168, 174, 177, 180, 182, 192, 195 and 197, wherein if the bio-distribution modifier comprised by the N-terminal modification group A is HAC2:HPD:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:HPD:HAC2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC2:HPD:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:HPD:HAC2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC4:HPD2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:HPD2:HAC4, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:HPD:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:HPD:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:HPD:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:HPD:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD4:HPD2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:HPD2:HPD4, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC2:HAC:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:HAC:HAC2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:HAC:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:HAC:HPD2, preferably if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:PEO2, or if the bio-distribution modifier comprised by the N-terminal modification group A is TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification f group A is HPD3:PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification f group A is HPD3:TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification f group A is TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS. Embodiment 209. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 127, 136, 141, 151, 156, 168, 177, 182, and 197, preferably the compound of any one of Embodiments 127, 136, 141, 151, 156, , 177, 182, 192 and 197, wherein if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO, or if the bio-distribution modifier comprised by the N-terminal modification group A is PEO2:Ahx, the bio-distribution modifier comprised by the C-terminal modification group C-term is lys:PEO2, or if the bio-distribution modifier comprised by the N-terminal modification group A is TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:TRIS:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:TRIS:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD2:PEO:Hyx, the bio-distribution modifier comprised by the C-terminal modification group C-term is prx:PEO:HPD2, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HAC3:TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS:HAC3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:PEO:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:PEO:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is HPD3:TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS:HPD3, or if the bio-distribution modifier comprised by the N-terminal modification group A is TRIS:Aur, the bio-distribution modifier comprised by the C-terminal modification group C-term is kur:TRIS. Embodiment 210. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 and 209, wherein the compound comprises three or more Z groups. Embodiment 211. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, preferably the compound of Embodiment 210, wherein the first of the three or more Z groups is the Z group comprised by the N-terminal modification group A, wherein the Z group comprises the bio-distribution modifier optionally comprising a linker, and the second of the three or more Z groups is the Z group comprised by the C-terminal modification group C-term, wherein the Z group comprises the bio-distribution modifier optionally comprising a linker, and the third of the three or more Z groups a) is covalently attached to or is part of substituent R4d, under the proviso that Xaa4 is a structure of formula (Va), (Vd) or (Ve), b) is covalently attached to or is part of substituent R4h, under the proviso that Xaa4 is a structure of formula (Vb) or (Vf), c) is covalently attached to or is part of substituent R5d, under the proviso that Xaa5 is a structure of formula (VIa), d) is covalently attached to or is part of substituent R8a, under the proviso that Xaa8 is a structure of formula (IXa) or (IXd), e) is covalently attached to or is part of substituent R8e, under the proviso that Xaa8 is a structure of formula (IXc), or f) is covalently attached to or is part of substituent RYd, under the proviso that Yc is a structure of formula (XIIIh), comprising a residue RYc, wherein to RYc a residue RYd is covalently attached, wherein RYd is a structure of formula (XIIIc), (XIIId) or (XIIIe). Embodiment 212. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 and 211, preferably the compound of any one of Embodiments 210 and 211, more preferably the compound of Embodiment 211, wherein the third of the three or more Z groups is a) is covalently attached to or is part of substituent R4d, under the proviso that Xaa4 is a structure of formula (Va), (Vd) or (Ve), b) is covalently attached to or is part of substituent R4h, under the proviso that Xaa4 is a structure of formula (Vb) or (Vf), c) is covalently attached to or is part of substituent R8a, under the proviso that Xaa8 is a structure of formula (IXa) or (IXd), or d) is covalently attached to or is part of substituent R8e, under the proviso that Xaa8 is a structure of formula (IXc). Embodiment 213. The compound of any one of Embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 and 209, preferably the compound of Embodiments 208 and 209, more preferably the compound of Embodiment 209, wherein the compound comprises three Z groups. Embodiment 214. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209 and 213, preferably the compound of any one of Embodiments 208, 209 and 213, more preferably the compound of any one of Embodiments 209 and 213, most preferably the compound of Embodiment 213, wherein the first of the three Z groups is the Z group comprised by the N-terminal modification group A, wherein the Z group comprises the bio-distribution modifier optionally comprising a linker, and the second of the three Z groups is the Z group comprised by the C-terminal modification group C-term, wherein the Z group comprises the bio-distribution modifier optionally comprising a linker, and the third of the three Z groups is a chelator optionally comprising a linker, preferably each and any linker comprises an amino group and a carbonyl group. Embodiment 215. The compound of any one of Embodiments , 213 and 214, preferably the compound of any one of Embodiments 208, 209, 213 and 214, more preferably the compound of any one of Embodiments 209, 213 and 214, most preferably the compound of Embodiment 214, wherein the chelator is covalently attached to or is part of substituent R8a, under the proviso that Xaa8 is a structure of formula (IXa) or (IXd). Embodiment 216. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209 and 213 to 215, preferably the compound of any one of Embodiments 208, 209 and 213 to 215, more preferably the compound of any one of Embodiments 209 and 213 to 215, most preferably the compound of Embodiment 215, wherein Xaa8 is Apc(R8a), wherein R8a is a chelator a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. Embodiment 217. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209 and 213 to 216, preferably the compound of any one of Embodiments 208, 209 and 213 to 216, more preferably the compound of any one of Embodiments 209 and 213 to 216, most preferably the compound of Embodiment 216, wherein Xaa8 is Apc(R8a), wherein R8a is a chelator, wherein the chelator is DOTA. Embodiment 218. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 213 and 214, preferably the compound of any one of Embodiments 208, 209, 213 and 214, more preferably the compound of any one of Embodiments 209,213 and 214, most preferably the compound of Embodiment 214, wherein the chelator is covalently attached to or is part of substituent R8e, under the proviso that Xaa8 is a structure of formula (IXc). Embodiment 219. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 213, 214 and 218, preferably the compound of any one of Embodiments 208, 209, 213, 214 and 218, more preferably the compound of any one of Embodiments 209, 213, 214 and 218, most preferably the compound of Embodiment 218, wherein Xaa8 is Amk(R8e), wherein R8e is a chelator a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. Embodiment 220. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 213, 214, 218 and 219, preferably the compound of any one of Embodiments 208, 209, 213, 214, 218 and 219, more preferably the compound of any one of Embodiments 209, 213, 214, 218 and 219, most preferably the compound of Embodiment 219, wherein Xaa8 is Amk(R8e), wherein R8e is a chelator, wherein the chelator is DOTA. Embodiment 221. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219 and 220, wherein the compound is selected from the group consisting of compound HPD2:Ahx-Asp-Trp-5Clw- Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-lys:HPD2 (GIP-1001) of the following formula compound PEO:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:PEO (GIP-1003) of the following formula , compound PEO:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:PEO (GIP-1004) of the following formula , compound PEO2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- lys:PEO2 (GIP-1005) of the following formula

[0002] , compound TRIS:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:TRIS (GIP-1006) of the following formula , compound HPD3:TRIS:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:TRIS:HPD3 (GIP-1007) of the following formula

[0003] , compound HAC3:PEO:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:PEO:HAC3 (GIP-1009) of the following formula

[0004] , compound HAC3:TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HAC3 (GIP-1011) of the following formula

[0005] , compound HPD3:TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HPD3 (GIP-1013) of the following formula

[0006] , compound TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:TRIS (GIP-1014) of the following formula , compound HPD2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:HPD2 (GIP-1015) of the following formula

[0007] , compound PEO:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:PEO (GIP-1017) of the following formula

[0008] , compound PEO:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:PEO (GIP-1018) of the following formula , compound PEO2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:PEO2 (GIP-1019) of the following formula

[0009] , compound TRIS:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:TRIS (GIP-1020) of the following formula , compound HPD3:TRIS:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-prx:TRIS:HPD3 (GIP-1021) of the following formula , compound HAC3:PEO:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-prx:PEO:HAC3 (GIP-1023) of the following formula

[0010] , compound HAC3:TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HAC3 (GIP-1025) of the following formula

[0011] , compound HPD3:TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HPD3 (GIP-1027) of the following formula

[0012] , compound TRIS:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:TRIS (GIP-1028) of the following formula compound HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- lys:HPD2 (GIP-1029) of the following formula

[0013] , compound HPD3:PEO:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:PEO:HPD3 (GIP-1030) of the following formula , compound PEO:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:PEO (GIP-1031) of the following formula

[0014] , compound PEO:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:PEO (GIP-1032) of the following formula , compound PEO2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- lys:PEO2 (GIP-1033) of the following formula

[0015] , compound TRIS:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:TRIS (GIP-1034) of the following formula , compound HPD3:TRIS:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:TRIS:HPD3 (GIP-1035) of the following formula

[0016] , compound HAC3:TRIS:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:TRIS:HAC3 (GIP-1036) of the following formula , compound HAC3:PEO:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:PEO:HAC3 (GIP-1037) of the following formula

[0017] , compound HAC3:TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HAC3 (GIP-1039) of the following formula

[0018] , compound HPD3:TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HPD3 (GIP-1041) of the following formula

[0019] , compound TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:TRIS (GIP-1042) of the following formula , compound HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:HPD2 (GIP-1043) of the following formula

[0020] , compound PEO:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:PEO (GIP-1045) of the following formula

[0021] , compound PEO:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:PEO (GIP-1046) of the following formula , compound PEO2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:PEO2 (GIP-1047) of the following formula

[0022] , compound TRIS:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:TRIS (GIP-1048) of the following formula compound HAC3:TRIS:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-prx:TRIS:HAC3 (GIP-1050) of the following formula , compound HAC3:TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HAC3 (GIP-1053) of the following formula compound HPD3:TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:TRIS:HPD3 (GIP-1055) of the following formula

[0023] , compound TRIS:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:TRIS (GIP-1056) of the following formula , compound HAC2:HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:HPD:HAC2 (GIP-1057) of the following formula

[0024] , compound HAC4:HPD2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HAC4 (GIP-1059) of the following formula

[0025] , compound HPD2:HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:HPD:HPD2 (GIP-1060) of the following formula , compound HPD2:HPD:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:HPD:HPD2 (GIP-1061) of the following formula

[0026] , compound HAC2:HAC:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:HAC:HAC2 (GIP-1063) of the following formula

[0027] , compound HAC2:HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:HPD:HAC2 (GIP-1065) of the following formula

[0028] , compound HPD2:HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:HPD:HPD2 (GIP-1068) of the following formula

[0029] , compound HPD4:HPD2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HPD4 (GIP-1070) of the following formula

[0030] , compound HPD2:HAC:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:HAC:HPD2 (GIP-1072) of the following formula

[0031] , compound HAC2:HPD:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:HPD:HAC2 (GIP-1074) of the following formula

[0032] , compound HAC4:HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HAC4 (GIP-1075) of the following formula , compound HPD2:HPD:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:HPD:HPD2 (GIP-1076) of the following formula

[0033] , compound HPD4:HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HPD4 (GIP-1078) of the following formula

[0034] , compound HPD2:HAC:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-kur:HAC:HPD2 (GIP-1080) of the following formula

[0035] , compound HAC4:HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HAC4 (GIP-1083) of the following formula compound HPD2:HPD:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-prx:HPD:HPD2 (GIP-1085) of the following formula

[0036] , compound HPD4:HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HPD4 (GIP-1086) of the following formula , compound HAC2:HAC:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-kur:HAC:HAC2 (GIP-1087) of the following formula

[0037] , compound HAC2:HAC:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HAC2 (GIP-1089) of the following formula

[0038] compound HAC2:HAC:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HAC2 (GIP-1090) of the following formula , compound HAC2:HPD:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HAC2 (GIP-1091) of the following formula

[0039] , compound HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:HPD (GIP-1092) of the following formula , compound HPD:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:HPD (GIP-1093) of the following formula

[0040] , compound HPD2:HAC:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HPD2 (GIP-1094) of the following formula , compound HPD2:HPD:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HPD2 (GIP-1095) of the following formula

[0041] , compound HAC:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:HAC (GIP-1096) of the following formula , compound HPD2:HAC:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HPD2 (GIP-1097) of the following formula

[0042] , compound HAC2:HPD:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HAC2 (GIP-1100) of the following formula , compound HPD:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:HPD (GIP-1101) of the following formula , compound HPD:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:HPD (GIP-1102) of the following formula , compound HPD2:HAC:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HPD2 (GIP-1103) of the following formula compound HAC:Aur-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:HAC (GIP-1105) of the following formula

[0043] , compound HPD2:HAC:Tzx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HPD2 (GIP-1106) of the following formula , compound HAC2:HAC:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HAC2 (GIP-1107) of the following formula

[0044] , compound HAC2:HAC:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HAC2 (GIP-1108) of the following formula , compound HAC2:HPD:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HAC2 (GIP-1109) of the following formula

[0045] , compound HPD:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:HPD (GIP-1110) of the following formula , compound HPD:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:HPD (GIP-1111) of the following formula

[0046] , compound HPD2:HAC:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HPD2 (GIP-1112) of the following formula , compound HPD2:HPD:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HPD2 (GIP-1113) of the following formula

[0047] , compound HAC:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- kur:HAC (GIP-1114) of the following formula , compound HPD2:HAC:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HPD2 (GIP-1115) of the following formula

[0048] , compound HAC2:HAC:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-lys:HAC:HAC2 (GIP-1116) of the following formula , compound HAC2:HAC:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HAC2 (GIP-1117) of the following formula

[0049] , compound HPD:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:HPD (GIP-1119) of the following formula , compound HPD:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:HPD (GIP-1120) of the following formula compound HPD2:HPD:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-tzk:HPD:HPD2 (GIP-1122) of the following formula

[0050] compound HAC:Aur-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- kur:HAC (GIP-1123) of the following formula compound HPD2:HAC:Tzx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]- APAc-tzk:HAC:HPD2 (GIP-1124) of the following formula

[0051] , compound HAC:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- lys:HAC (GIP-1125) of the following formula , compound HAC:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:HAC (GIP-1126) of the following formula

[0052] , compound HAC:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:HAC (GIP-1127) of the following formula , compound HAC:Hyx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:HAC (GIP-1128) of the following formula

[0053] , compound HAC:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- lys:HAC (GIP-1129) of the following formula , compound HAC:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc- prx:HAC (GIP-1130) of the following formula

[0054] , compound HAC:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- lys:HAC (GIP-1131) of the following formula , and compound HAC:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc- prx:HAC (GIP-1132) of the following formula

[0055] . Embodiment 222. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220 and 221, preferably the compound of Embodiment 221, wherein the compound is selected from the group consisting of GIP-1001 to GIP-1132, preferably is selected from the group consisting of GIP-1001 to GIP-1124, more preferably is selected from the group consisting of GIP-1001 to GIP-1088 and most preferably is selected from the group consisting of GIP-1001 to GIP-1056. Embodiment 223. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221 and 222, preferably the compound of any one of Embodiments 221 and 222, more preferably the compound of Embodiment 222, wherein the compound is selected from the group consisting of GIP-1001 to GIP-1056, preferably is selected from the group consisting of GIP-1001 to GIP-1042, more preferably is selected from the group consisting of GIP-1001 to GIP-1028 and most preferably is selected from the group consisting of GIP-1001 to GIP-1014. Embodiment 224. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221 and 222, preferably the compound of any one of Embodiments 221 and 222, more preferably the compound of Embodiment 222, wherein the compound is selected from the group consisting of GIP-1057 to GIP-1088, preferably is selected from the group consisting of GIP-1057 to GIP-1080, more preferably is selected from the group consisting of GIP-1057 to GIP-1072 and most preferably is selected from the group consisting of GIP-1057 to GIP-1064. Embodiment 225. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223 and 224, wherein any S-atom, which can be oxidized, preferably any sulfur atom of a thioether group, is present as -S-, -S(O)- or -S(O2)- or a mixture thereof. Embodiment 226. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224 and 225, wherein the compound comprises a diagnostically active radionuclide, wherein the radionuclide is a radionuclide used for diagnosis, preferably is selected from the group comprising 43Sc, 44Sc, 51Mn, 52Mn, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, 94mTc, 99mTc, 111In, 152Tb, 155Tb, 177Lu, 201Tl, 203Pb, 18F, 76Br, 77Br, 123I, 124I, and 125I, more preferably is selected from the group comprising 43Sc, 44Sc, 64Cu, 67Ga, 68Ga, 86Y,89Zr, 111In, 152Tb, 155Tb, and 203Pb, and most preferably is selected from the group comprising 64Cu, 68Ga, 111In and 203Pb. Embodiment 227. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224 and 225, wherein the compound comprises a therapeutically active radionuclide, wherein the radionuclide is a radionuclide used for therapy, preferably is selected from the group comprising 47Sc, 67Cu, 89Sr, 90Y, 111In, 153Sm, 149Tb, 161Tb, 177Lu, 186Re, 188Re, 212Pb, 213Bi, 223Ra, 225Ac, 226Th, 227Th, 131I, and 211At, more preferably is selected from the group comprising 47Sc, 67Cu, 90Y, 177Lu, 212Pb, 213Bi, 225Ac, and 227Th, and most preferably is selected from the group comprising 90Y, 177Lu, 212Pb, 225Ac, and 227Th. Embodiment 228. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225 and 226, preferably the compound of Embodiment 226, for use in a method of diagnosing a disease. Embodiment 229. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227, preferably the compound of Embodiment 227, for use in a method for the treatment of a disease. Embodiment 230. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227, for use in a method for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the identification of a subject comprises carrying out a method of diagnosing a disease using a compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227. Embodiment 231. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227, for use in a method for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the selection of a subject from a group of subjects comprises carrying out a method of diagnosing a disease using a compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227. Embodiment 232. The compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227, for use in a method for the stratification of a group of subjects into subjects which are likely to respond to a treatment of a disease, and into subjects which are not likely to respond to a treatment of a disease, wherein the method for the stratification of a group of subjects comprises carrying out a method of diagnosing a disease using a compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227. Embodiment 233. The compound for use of any one of Embodiments 228, 229, 230, 231 and 232, wherein the disease is cancer. Embodiment 234. The compound for use of Embodiment 233, wherein the cancer is expressing Gastric Inhibitory Peptide Receptor (GIPR), preferably, the cancer is overexpressing GIPR. Embodiment 235. The compound for use of any one of Embodiments 233 and 234, wherein the cancer is a neuroendocrine cancer or a neuroendocrine neoplasm. Embodiment 236. The compound for use of any one of Embodiment 233, 234 and 235, wherein the cancer is selected from the group consisting of medullary thyroid cancer, gastrointestinal neuroendocrine neoplasms, ileal neuroendocrine neoplasms, pancreatic neuroendocrine neoplasms, nonfunctioning neuroendocrine neoplasms, Insulinomas, Gastrinomas, Glucagonomas, VIPomas, Somatostatinoma, ACTHoma, lung neuroendocrine neoplasms, typical carcinoid tumors, atypical carcinoid tumors, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumors, Merkel cell carcinoma, Pheochromocytoma of the adrenal gland, adrenal cancer, parathyroid cancer, paraganglioma, pituitary gland tumors, neuroendocrine tumors of the ovaries and neuroendocrine tumors of the testicles. Embodiment 237. The compound for use of any one of Embodiments 228, 229, 230, 231 and 232, wherein the disease is a metabolic disease. Embodiment 238. The compound for use of Embodiment 237, wherein a diseased cell and / or a diseased tissue, preferably a diseased cell and / or a diseased tissue of the metabolic disease expresses GIPR. Embodiment 239. The compound for use of Embodiment 238, wherein the diseased cell and / or the diseased tissue overexpresses GIPR. Embodiment 240. The compound for use of any one of Embodiments 238 and 239, wherein the diseased cell is a pancreatic cell. Embodiment 241. The compound for use of any one of Embodiments 237, 238, 239 and 240, wherein the metabolic disease is selected from the group consisting of type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose, and impaired glucose tolerance. Embodiment 242. A composition comprising a compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227 and a pharmaceutically acceptable excipient. Embodiment 243. The composition of Embodiment 242, wherein the composition is a pharmaceutical composition. Embodiment 244. A kit comprising a compound of any one of Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 and 227 and one or more optional excipient(s) and optionally one or more device(s). Embodiment 245. The kit of Embodiment 244, wherein the device(s) is / are selected from the group comprising a labeling device, a purification device, a handling device, a radioprotection device, an analytical device or an administration device. In accordance with the present invention, the compound of the present invention as subject to Embodiment 1 will also be referred to herein as the first aspect of the present invention. In accordance with the present invention, the compound of the present invention according to the first aspect of the present invention, including any embodiment thereof, for use in a method of diagnosing a disease as subject to Embodiment 228 will also be referred to herein as the second aspect of the present invention. In accordance with the present invention, the compound of the present invention according to the first aspect of the present invention, including any embodiment thereof, for use in a method for the treatment of a disease as subject to Embodiment 229 will also be referred to herein as the third aspect of the present invention. In accordance with the present invention, the compound of the present invention according to the first aspect including any embodiment thereof, for use in a method for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the identification of a subject comprises carrying out a method of diagnosing a disease using a compound according to the first aspect of the present invention, including any embodiment thereof, as subject to Embodiment 230 will also be referred to herein as the fourth aspect of the present invention. In accordance with the present invention, the compound of the present invention according to the first aspect including any embodiment thereof, for use in a method for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the selection of a subject from a group of subjects comprises carrying out a method of diagnosing a disease using a compound according to the first aspect of the present invention, including any embodiment thereof, as subject to Embodiment 231 will also be referred to herein as the fifth aspect of the present invention. In accordance with the present invention, the compound of the present invention according to the first aspect including any embodiment thereof, for use in a method for the stratification of a group of subjects into subjects which are likely to respond to a treatment of a disease, and into subjects which are not likely to respond to a treatment of a disease, wherein the method for the stratification of a group of subjects comprises carrying out a method of diagnosing a disease using a compound according to the first aspect of the present invention, including any embodiment thereof, as subject to Embodiment 232will also be referred to herein as the sixth aspect of the present invention. In accordance with the present invention, the composition as subject to Embodiment 242 comprising a compound according to the first aspect of the present invention, including any embodiment thereof, and a pharmaceutically acceptable excipient will also be referred to herein as the seventh aspect of the present invention. In accordance with the present invention, the kit as subject to Embodiment 244 comprising a compound according to the first aspect of the present invention, including any embodiment thereof, and one or more optional excipient(s) and optionally one or more device(s) will also be referred to herein as the eighth aspect of the present invention. According to the present invention, each and any embodiment of the compound of the first aspect is also an embodiment of the peptide of the second aspect, and vice versa. The present inventors have surprisingly found that the compounds of the invention show a high affinity to Gastric Inhibitory Peptide Receptor (GIPR). Furthermore, the present inventors have surprisingly found that compounds of the invention show other characteristics, which predestine the compounds of the invention for use in the diagnosis and therapy of diseases involving Gastric Inhibitory Peptide Receptor (GIPR). Such other characteristics comprise high stability in plasma and selectivity for Gastric Inhibitory Peptide Receptor (GIPR). Another surprising characteristic of the compounds of the invention is a low retention in normal, i.e. non-diseased tissues. According to the present invention, the compounds of the invention may comprise a bio- distribution modifier comprised by an N-terminal modification group A and a bio-distribution modifier comprised by a C-terminal modification group C-term, which is / are either directly or by means of a linker attached. More preferably, the chelator is attached to Xaa8. In an embodiment and as preferably used herein, a diagnostically active compound is a compound, which is suitable for or useful in the diagnosis of a disease. In an embodiment and as preferably used herein, a diagnostic agent or a diagnostically active agent is a compound, which is suitable for or useful in the diagnosis of a disease. In an embodiment and as preferably used herein, a therapeutically active compound is a compound, which is suitable for or useful in the treatment of a disease. In an embodiment and as preferably used herein, a therapeutic agent or a therapeutically active agent is a compound, which is suitable for or useful in the treatment of a disease. In an embodiment and as preferably used herein, a theragnostically active compound is a compound, which is suitable for or useful in both the diagnosis and therapy of a disease. In an embodiment and as preferably used herein, a theragnostic agent or a theragnostically active agent is a compound, which is suitable for or useful in both the diagnosis and therapy of a disease. In an embodiment and as preferably used herein, theragnostics is a method for the combined diagnosis and therapy of a disease; preferably, the combined diagnostically and therapeutically active compounds used in theragnostics are radiolabeled. In an embodiment and as preferably used herein, treatment of a disease is treatment and / or prevention of a disease. In an embodiment and as preferably used herein, pEC50 is determined in a FACS binding assay, wherein the FACS binding assay is as described in the example part. In an embodiment and as preferably used herein, pIC50 is determined in a FACS binding assay, wherein the FACS binding assay is as described in the example part. In an embodiment and as preferably used herein, a disease involving GIPR is a disease, wherein cells including but not limited to tumor cells expressing or pancreatic beta cells, preferably in an upregulated manner, GIPR and tissue either expressing GIPR, preferably in an upregulated manner respectively, are either a or the cause for the disease and / or the symptoms of the disease, or are part of the pathology underlying the disease. A preferred GIPR-expressing cell is a tumor cell. In an embodiment of the disease, preferably when used in connection with the treatment, treating and / or therapy of the disease, affecting the cells, the tissue and pathology, respectively, results in cure, treatment or amelioration of the disease and / or the symptoms of the disease. In an embodiment of the disease, preferably when used in connection with the diagnosis and / or diagnosing of the disease, labeling of the GIPR-expressing cells and / or of the GIPR-expressing tissue allows discriminating or distinguishing said cells and / or said tissue from healthy or GIPR-non-expressing cells and / or healthy or GIPR-non-expressing tissue. More preferably such discrimination or distinction forms the basis for said diagnosis and diagnosing, respectively. In an embodiment thereof, labeling means the interaction of a detectable label either directly or indirectly with the GIPR-expressing cells and / or with the GIPR-expressing tissue or tissue containing such GIPR-expressing cells; more preferably such interaction involves or is based on the interaction of the label or a compound bearing such label with GIPR. In an embodiment and as preferably used herein, a target cell is a cell, which is expressing GIPR and is a or the cause for a disease and / or the symptoms of a disease, or is part of the pathology underlying a disease. In an embodiment and as preferably used herein, a non-target cell is a cell, which is either not expressing GIPR and / or is not a or the cause for a disease and / or the symptoms of a disease, or is part of the pathology underlying a disease. In an embodiment and as preferably used herein, a neoplasm is an abnormal new growth of cells. The cells in a neoplasm grow more rapidly than normal cells and will continue to grow if not treated. A neoplasm may be benign or malignant. In an embodiment and as preferably used herein, a tumor is a mass lesion that may be benign or malignant. In an embodiment and as preferably used herein, a cancer is a malignant neoplasm. In an embodiment and as preferably used herein, a cell and / or tissue expressing GIPR is overexpressing GIPR. More preferably, GIPR is overexpressed if the extent of expression is one observed in a cell and / or tissue of a person diagnosed to suffer from the disease, preferably the disease being cancer and metabolic disease as disclosed herein. Accordingly, the compounds of the invention are thus particularly suitable for and useful in the diagnosis and treatment, respectively, of these diseases. Insofar, the above indications are indications, which can be treated by the compound of the invention. It will be understood by the person skilled in the art that also metastases and metastases of the above indications in particular can be treated and diagnosed by the compound of the invention and the methods of diagnosis and methods of treatment making use of the compound of the invention. It is also within the present invention that the compound of the invention is used or is for use in a method for the treatment of a disease as disclosed herein. Such method, preferably, comprises the step of administering to a subject in need thereof a therapeutically effective amount of the compound of the invention. Such method includes, but is not limited to, curative or adjuvant cancer treatment. It is used as palliative treatment, wherein cure is not possible and the aim is for local disease control or symptomatic relief or as therapeutic treatment, wherein the therapy has survival benefit and it can be curative. The method for the treatment of a disease as disclosed herein, includes the treatment of the disease disclosed herein, including tumors and cancer as well as metabolic diseases, and may be used either as the primary therapy or as second, third, fourth or last line therapy. It is also within the present invention to combine the compound of the invention with further therapeutic approaches. It is well known to the person skilled in the art that the precise treatment intent including curative, adjuvant, neoadjuvant, therapeutic, or palliative treatment intent will depend on the tumor type, location, and stage, as well as the general health of the patient. Without wishing to be bound by any theory, the therapeutic effect of the compounds of present invention is based on the delivery of a radionuclide to a diseased GIPR expressing cell or structure, which is destroyed by the radiation emitted by the radionuclide. Preferably, GIPR is overexpressed by such cell or structure. Without wishing to be bound by any theory, the therapeutic use of the compounds of the invention arises from the binding of said compounds to GIPR expressing cells, cancer cells in particular, wherein said cells are killed by the radiation emitted by the radionuclide. It will also be appreciated by a person skilled in the art that GIPR is a pan-neuroendocrine-tumor target. Because of this, any respective cancer and tumor can be treated and diagnosed, respectively. In an embodiment of the present invention, the disease is selected from the group comprising a cancer and tumor, respectively, expressing GIPR, preferably over-expressing GIPR. In a preferred embodiment, the cancer is a neuroendocrine cancer or neuroendocrine tumor, preferably each and any expressing or overexpressing GIPR. In a further embodiment, the diseases is selected from the group comprising medullary thyroid cancer, gastrointestinal neuroendocrine neoplasms, ileal neuroendocrine neoplasms, pancreatic neuroendocrine neoplasms, nonfunctioning neuroendocrine neoplasms, Insulinomas, Gastrinomas, Glucagonomas, VIPomas, Somatostatinoma, ACTHoma, lung neuroendocrine neoplasms, typical carcinoid tumors, atypical carcinoid tumors, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumors, Merkel cell carcinoma, Pheochromocytoma of the adrenal gland, adrenal cancer, parathyroid cancer, paraganglioma, pituitary gland tumors, neuroendocrine tumors of the ovaries and neuroendocrine tumors of the testicles. In a further embodiment, the disease is a metabolic disease. Preferably, the metabolic disease is one where GIPR is expressed, more preferably where GIPR is overexpressed in pancreatic beta cells. In a still further embodiment, the disease is selected from the group comprising metabolic diseases and disorders, preferably type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose, and impaired glucose tolerance. In an embodiment, the compounds of the present invention are used to detect cells and tissues overexpressing the GIPR, whereby such detection is achieved by conjugating a detectable label to the compounds of the invention, preferably a detectable radionuclide. In a preferred embodiment, the cells and tissues detected are diseased cells and tissues and / or are either a or the cause for the disease and / or the symptoms of the disease, or are part of the pathology underlying the disease. In a further preferred embodiment, the diseased cells and tissues are causing and / or are part of an oncology indication (e.g., neoplasms, tumors, and cancers). In another embodiment, the compounds of the present invention are used to treat cells and tissues overexpressing the GIPR. In a preferred embodiment, the cells and tissues treated are diseased cells and tissues and / or are either a or the cause for the disease and / or the symptoms of the disease, or are part of the pathology underlying the disease. In a further preferred embodiment, the diseased cells and tissues are causing and / or are part of an oncology indication (e.g. neoplasms, tumors, and cancers) and the therapeutic activity is achieved by conjugating therapeutically active effector to the compounds of the present invention, preferably a therapeutically active radionuclide. An effective amount is a dosage of the compound...

Claims

3B Pharmaceuticals GmbH D 10043 PCT Claims 1. A compound comprising a cyclic peptide of formula (Ia)or a cyclic peptide of formula (Ib)(Ib) each comprising an N-terminal modification group A attached to Xaa1, and each comprising a C-terminal group C-term attached to Xaa11, wherein the peptide sequence is drawn from left to right in N- to C-terminal direction, the N-terminal modification group A comprises a Z group, wherein a linker is optionally interspersed between the Z group and Xaa1, wherein the Z group comprises a bio-distribution modifier, Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, wherein the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2, 1Xaa2 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa2 is a residue of an α-amino acid with a side chain comprising a heteroaryl ring, wherein the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3, Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring, wherein the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4, Xaa4 is a residue of an α-amino acid optionally comprising a Z group or is a residue of an N-alkylated α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5, Xaa5 is a residue of an α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6, Xaa6 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group, wherein the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7, 2Xaa7 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, wherein the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8, Xaa8 is a residue of an α-amino acid optionally comprising a Z group, wherein the Z group is a chelator or a bio-distribution modifier, wherein the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9, Xaa9 is a residue of an α-amino acid, wherein the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10, Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring, wherein the carbonyl group of Xaa10 is covalently attached to the α-nitrogen atom of Xaa11, Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, the C-terminal modification C-term comprises a Z group, wherein a linker is optionally interspersed between the Xaa11 and the Z group, wherein the Z group comprises a bio-distribution modifier, 3wherein Xaa7 and Xaa11 are indirectly linked or directly covalently linked to each other forming a macrocyclic ring, wherein if Xaa7 and Xaa11 are indirectly linked forming a cyclic peptide of formula (Ia), the heteroatom of Xaa7 and the heteroatom of Xaa11 are linked through a ring interspersed between the heteroatom of Xaa7 and the heteroatom of Xaa11 forming Yc, wherein the ring is a heteroaryl ring, an aryl ring optionally comprising a Z group or a heterocyclic ring, wherein the heteroatom is each and individually selected from the group consisting of a sulfur atom and a nitrogen atom, wherein if the heteroatom of Xaa7 is a sulfur atom, a thioether bond covalently links Xaa7 to the ring, if the heteroatom of Xaa7 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa7 to the ring, if the heteroatom of Xaa11 is a sulfur atom, a thioether bond covalently links Xaa11 to the ring, and if the heteroatom of Xaa11 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa11 to the ring, or wherein if Xaa7 and Xaa11 are directly covalently linked forming a cyclic peptide of formula (Ib), the heteroatom of Xaa7 is a sulfur atom and the heteroatom of Xaa11 is a sulfur atom forming a disulfide bond, and wherein each and any of the bio-distribution modifiers of the N-terminal modification group A, Xaa4, Xaa5 and Xaa8 comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom or a triazolyl moiety is covalently attached, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more 4hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group wherein, if the bio-distribution modifier is comprised by the N-terminal modification group A, (a) the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the α-nitrogen atom of Xaa1, or (b) if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier and Xaa1 the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the linker and the carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1, or wherein, if the bio-distribution modifier is comprised by Xaa4 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa4, or wherein, if the bio-distribution modifier is comprised by Xaa5 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa5, or wherein, if the bio-distribution modifier is comprised by Xaa8 comprising an amino group in the side chain, the carbonyl group of the aliphatic carboxylic acid of the bio-distribution modifier is covalently attached to the amino group of the side chain of Xaa8, and wherein the bio-distribution modifier comprised by the C-terminal modification group C-term comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the side chain of the α-amino acid a nitrogen atom or a triazolyl moiety is covalently attached, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or 5more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein (a) the carbonyl group of Xaa11 is covalently attached to the α-nitrogen atom of the α-amino acid of the bio-distribution modifier, or (b) if a linker comprising an amino group and a carbonyl group is interspersed between the Xaa11 and the bio-distribution modifier, the carbonyl group of Xaa11 is covalently attached to the amino group of the linker and the carbonyl group of the linker is covalently attached to the α-nitrogen atom of the α-amino acid, and wherein to the carbonyl group of the α-amino acid of the bio-distribution modifier an amino group is covalently attached thereby forming an amide.

2. The compound of claim 1, wherein Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, preferably Xaa1 is a residue of an α-amino acid of formulae (IIa), (IIb) or (IIc), more preferably Xaa1 is a residue of an α-amino acid of formula (IIa),wherein 6the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom of Xaa1, or if a linker, comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1, R1a is selected from the group consisting of H and (C1-C4)alkyl, R1b is selected from the group consisting of CO2H, SO3H, OPO3H2, CONH2 and OH, R1c is selected from the group consisting of H, OH and (C1-C2)alkyl under the proviso that R1b is selected from the group consisting of CO2H, SO3H and CONH2, or is selected from the group consisting of H and (C1-C2)alkyl under the proviso that R1b is selected from the group consisting of OH and OPO3H2, R1d is selected from the group consisting of H and (C1-C2)alkyl, preferably if R1c is (C1-C2)alkyl, R1d is the same (C1-C2)alkyl, R1e is selected from the group consisting of H, OH and (C1-C2)alkyl, R1f is selected from the group consisting of H and (C1-C2)alkyl, preferably if R1e is (C 1f 1-C2)alkyl, R is the same (C1-C2)alkyl, and the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2, Xaa2 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa2 is a residue of an α-amino acid of formulae (IIIa) or (IIIb), more preferably a residue of an α-amino acid of formula (IIIa),7wherein X2a is selected from the group consisting of NH, NCH3 and S, preferably selected from the group consisting of NH and S, X2b is selected from the group consisting of N, C-H, C-F and C-CH3, preferably selected from the group consisting of N and C-H, R2a is selected from the group consisting of H, a halogen, methyl and OCH3, preferably R2a is selected from the group consisting of H and F, R2b is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2b is selected from the group consisting of H, Cl and Br, R2c is selected from the group consisting of H, OH, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of F, Cl and Br, more preferably R2c is selected from the group consisting of H, F and OH, R2d is selected from the group consisting of H, a halogen, methyl and OCH3, wherein the halogen is selected from the group consisting of F, Cl and Br, preferably R2d is H, R2e is selected from the group consisting of H, a halogen and methyl, preferably the halogen is Cl, more preferably R2e is H, R2f is selected from the group consisting of H and OCH3, preferably R2f is H, R2g is selected from the group consisting of H, OH, methyl and OCH3, preferably R2g is H, or (b), under the proviso that Xaa3 is of formulae (IVa) or (IVb), preferably under the proviso that Xaa3 is of formula (IVa), Xaa2 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an aryl ring, preferably Xaa2 is a residue of an α-amino acid of formula (IIIc)wherein 8R2h is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2h is H, Cl or Br, R2i is selected from the group consisting of H, methyl, C(CH3)3, CF3, OH, OCH3, OCH2CH3,OCF3, CONH2, CO2H and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2i is selected from the group consisting of H, Cl and Br, R2k is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2k is selected from the group consisting of H, Cl and Br, R2m is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and a halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R2m is selected from the group consisting of H, Cl and Br, and the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3, Xaa3 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring, preferably Xaa3 is a residue of an α-amino acid of formulae (IVa) or (IVb), more preferably Xaa3 is a residue of an α-amino acid of formula (IVa),wherein X3a is selected from the group consisting of NH, NCH 3a 3 and S, preferably X is selected from the group consisting of NH and S, 9X3b is selected from the group consisting of C-H, C-F, C-Cl, C-Br, C-CH3, C-OCH and N, preferably 3b 3 X is selected from the group consisting of C-H and C-F, X3c is selected from the group consisting of C-H and N, preferably X3c is C-H, R3b is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of F and Cl, more preferably R3b is selected from the group consisting of H and F, R3c is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is selected from the group consisting of Cl, Br and F, more preferably R3c is selected from the group consisting of Cl and Br, R3d is selected from the group consisting of H, a halogen, methyl and OCH3, preferably the halogen is F, R3e is selected from the group consisting of H, a halogen and methyl, preferably the halogen is Cl, R3f is selected from the group consisting of H and OCH3, R3g is selected from the group consisting of H, F, OH, methyl and OCH3, or (b) under the proviso that Xaa2 is an amino acid residue of formula (IIIa), Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an aryl ring, preferably Xaa3 is a residue of an α-amino acid of formulae (IVc) or (IVd)wherein R3h is selected from the group consisting of a halogen, OH, methyl, CF3, OCH3, OCF3and CONH2, preferably the halogen is selected from the group consisting of Cl and Br, R3i is selected from the group consisting of a halogen, OH, methyl, CF3, OCH3, OCF3 and CONH2, preferably the halogen is selected from the group consisting of Cl and Br, 10and the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4, Xaa4 is (a) a residue of a cyclic non-aromatic α-amino acid, preferably Xaa4 is a residue of an α-amino acid of formula (Va)wherein R4a is selected from the group consisting of H, OH, methyl and CF3, R4b is selected from the group consisting of H and methyl, preferably R4b is methyl if R4a is methyl, X4 is selected from the group consisting of CHR4c, S and O, wherein R4c is selected from the group consisting of NH2, OH, H, NHR4d, methyl and F, preferably R4c is NH2 or OH, wherein R4d is selected from the group consisting of Ac and a Z group, m is 1 or 2, preferably m is 1, or (b) a residue of an N-alkylated α-amino acid, preferably Xaa4 is a residue of an N-alkylated α-amino acid of formula (Vb)wherein n is 0, 1, 2, 3, 4, or 5, preferably n is 0, 1 or 3, R4e is, if n is 0, selected from the group consisting of H, methyl, an aryl ring, COOH, CONH 4h 2 and C(=O)R , or is, if n is 1, 2, 3, 4 or 5, selected from the group consisting of H, methyl, an aryl ring, OH, NH2, COOH, CONH2and NHR4h, R4f is selected from the group consisting of H and (C1-C2)alkyl, R4g is selected from the group consisting of H and methyl, R4h is a Z group, preferably the Z group is a bio-distribution modifier, 11or (c) Xaa4 is a residue of a bicyclic non-aromatic α-amino acid, preferably Xaa4 is a residue of a bicyclic non-aromatic α-amino acid of formula (Vc)wherein o is 1 or 2, and the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5, Xaa5 is (a) a residue of an α-amino acid optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by (C1-C4)alkyl or (b) a cyclic α-amino acid, and the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6, Xaa6 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group, preferably Xaa6 is a residue of an α-amino acid of formula (VIIa)(VIIa), wherein p is 1, 0 or 2, preferably p is 1, R6a is (C1-C2)alkyl, R6b is methyl, R6c is H, if p is 0, or is selected from the group consisting of H and methyl, if p is 1 or 2, and the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7, Xaa7 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a 12heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa7 is a residue of an α-amino acid of formula (VIIIa)wherein X7 comprises the heteroatom and is selected from the group consisting of – S– and –NH–, q is 1 or 2, preferably q is 1, and the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8, Xaa8 is (a) a residue of an aliphatic cyclic α-amino acid, of an aliphatic heterocyclic α-amino acid or of an aliphatic cyclic α-amino acid comprising an annulated aromatic ring, preferably Xaa8 is a residue of an α-amino acid of formula (IXa) or (IXb), more preferably Xaa8 is a residue of an α-amino acid of formula (IXa),wherein X8 is selected from the group consisting of NR8a, O, NH, and CH2, wherein R8a is a Z group or R8a is acetyl, wherein if R8a is a Z goup, the Z group preferably is a chelator optionally comprising a linker, r is 2 or 1, preferably r is 2, s is 1 or 2, preferably s is 1, t is 1 or 2, preferably t is 1 if s is 1, and t is 2 if s is 2, or (b) a residue of an α-amino acid or an α-alkyl-α-amino acid, preferably Xaa8 is a residue of an α-amino acid of formula (IXc), 13wherein R8b is selected from the group consisting of H, OH, NH2, NHR8e, (C1-C2)alkyl, COOH, CONH2, an aryl ring and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indoyl, wherein R8e is a Z group, preferably the Z group is a chelator optionally comprising a linker, R8c is selected from the group consisting of H and methyl, if R8b is selected from the group consisting of OH, NH2and NHR8e, or is selected from the group consisting of H, methyl and OH, if R8b is selected from the group consisting of H, (C1-C2)alkyl, COOH, CONH2, an aryl ring and a heteroaryl ring, R8d is selected from the group consisting of H and (C1-C2)alkyl, u is 0, 1, 2, 3, 4, or 5, preferably u is 0, 1 or 3, and the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9, Xaa9 is a residue of an acyclic α-amino acid, wherein the acyclic α-amino acid is inL- configuration and the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10, Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring, preferably Xaa10 is a residue of an α-amino acid of formula (XIa),wherein R10a is selected from the group consisting of (C1-C2)alkyl and phenyl, R10b is selected from the group consisting of methyl and H, 14R10c is selected from the group consisting of H and methyl, w is 0 or 1, and the carbonyl group of Xaa10 is covalently attached to the α-nitrogen atom of Xaa11, Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa11 is an α-amino acid of formula (XIIa),(XIIa), wherein X11 comprises the heteroatom and is selected from the group consisting of –S– and –NH–, R11c is the C-terminal group C-term, x is 1 or 2, and wherein a linker is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio- distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to the ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom or a triazolyl moiety, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and 15wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-I),wherein XA comprises a nitrogen atom or a triazolyl moiety, a1is 0, 1, 2, 3, 4, 5, or 6, if XA is a triazolyl moiety, preferably a1is 2, if XA is a nitrogen atom, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-II),wherein b1is 0 or 1, wherein, if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1 is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III),and 16RA2 is absent, if XA is a triazolyl moiety, or RA2 is a first level alkyl group of a structure of formula (A-II), if XA is a nitrogen atom, wherein b1is 0, wherein RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III) or RA3 and RA4 are H, and wherein the carbonyl group of the structure (A-I) is covalently attached to the α-nitrogen atom of Xaa1, or if a linker, comprising an amino group and a carbonyl group, is interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the structure (A-I) is covalently attached to the amino group of the linker, and wherein a linker is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom or a triazolyl moiety is covalently attached, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, 17and wherein to the carbonyl group attached to the α-carbon atom of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-I),wherein XC comprises a nitrogen atom or a triazolyl moiety, a4 is 0, 1, 2, 3, or 4, if XC is a triazolyl moiety, preferably a4 is 1 or 2, more preferably a4 is 1 if XC is a nitrogen atom, preferably a4is 3, RC1 is a first level alkyl group of a structure of formula (C-II),wherein b3 is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are each H, or wherein, if b3is 1, each and any of RC3, RC4 and RC5 is selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is a second level alkyl group of a structure of formula (C-III),and RC2 is absent, if XC is a triazolyl moiety, or RC2 is a first level alkyl group of a structure of formula (C-II), if XC is a nitrogen atom, wherein b3is 0, 18wherein, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are each H, and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising a carbonyl group and an amino group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably a linker is interspersed between Xaa11 and the bio-distribution comprised by the C-terminal modification group C-term.

3. The compound of any one of claims 1 and 2, wherein (a) Xaa7 is a residue of formula (VIIIa)Yc is a structure of formula (XIIIa)wherein RYa is –CH2–, RYb is –CH2–, Y1 is selected from the group consisting of N and CH, Y2 is selected from the group consisting of CH and N, 19and Xaa11 is a residue of formula (XIIa)(XIIa), wherein X11 is –S– or –NH–,is the C-terminal group C-term,is 1 or 2, preferably x is 1, preferably the compound comprises a cyclic peptide of formula (Ic),, more preferably the compound comprises a cyclic peptide of formula (Ic), wherein X7 is –S–, X11 is –S–, Y1 is N or CH, Y2 is CH, q is 1, and x is 1, most preferably the compound comprises a cyclic peptide of formula (Ic), wherein X7 is –S–, X11 is –S–, Y1 is N, Y2 is CH, q is 1, and x is 1, or (b) Xaa7 is a residue of formula (VIIIa)wherein X7 is –S– or –NH–, q is 1 or 2, preferably q is 1, Yc is a structure of formula (XIIIh)(XIIIh), 20wherein RYa is –CH2–, RYb is –CH2–, and RYc is –CH2–RYd, and RYd is a structure of formulae (XIIIc), (XIIId) or (XIIIe),wherein RYe and RYf are each and independently selected from the group consisting of H and (C1-C4)alkyl, i is each and independently 1, 2, 3, 4, 5 or 6, preferably i is 1 or 2, j and k are each and independently 1, 2 or 3, and X is O or S, preferably X is S, wherein in formulae (XIIIc) and (XIIIe) one of the two nitrogen atoms is covalently attached to –CH2– of RYc and in formula (XIIId) -X- is covalently attached to -CH2– of RYc while to the remaining nitrogen atom optionally a Z group is covalently attached, preferably the Z group comprises a chelator and optionally a linker, and Xaa11 is a residue of formula (XIIa)(XIIa), wherein X11 is –S– or –NH–, R11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1, 21preferably the compound comprises a cyclic peptide of formula (Ii),, more preferably the compound comprises a cyclic peptide of formula (Ii), wherein X7 is –S– and X11 is –S–, RYc is –CH2–RYd, and RYd is a structure of formulae (XIIId) or (XIIIe), wherein RYf is H, i is 1, j is 1, and k is 1, wherein in formula (XIIId) –X– is S and is attached to –CH Yc 2– of R , and in formula (XIIIe) one of the two nitrogen atoms is attached to -CH2– of RYc, while to the remaining nitrogen atom in either (XIIId) or (XIIIe) optionally a Z group is covalently attached, preferably the Z group comprises a chelator and optionally a linker, q is 1, and x is 1, most preferably the compound comprises a cyclic peptide of formula (Ii), wherein RYd is a structure of formula (XIIId), wherein –X– is S and RYf is H, and i is 1, preferably Yc is selected from the group comprising 2Lut, 3Lut, 3MeBn, tMeBn(DOTA-AET) and tMeBn(DOTA-PP), Xaa7 is selected from the group comprising Cys, Hcy and Dap, Xaa11 is selected from the group comprising Cys, Hcy and Dap, more preferably Yc is selected from the group comprising 2Lut and 3MeBn, Xaa7 is Cys and Xaa11 is Cys most preferably Yc is 2Lut, Xaa7 is Cys and Xaa11 is Cys.

4. The compound of any one of claims 1 to 3, wherein Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group within the side chain, preferably Xaa1 is a residue of an α-amino acid of formulae (IId) or (IIe), more preferably Xaa1 is a residue of an α-amino acid formula (IId), 22wherein R1a is selected from the group consisting of H and methyl, R1b is selected from the group consisting of CO2H, CONH2, OH, SO3H and OPO3H2, and wherein the carbonyl group of the aliphatic carboxylic acid comprised by the bio- distribution modifier comprised by the N-terminal modification group A is covalently attached to the α-nitrogen atom Xaa1, or if a linker comprising an amino group and a carbonyl group is interspersed between the bio-distribution modifier comprised by the N- terminal modification group A and Xaa1, a carbonyl group of the linker is covalently attached to the α-nitrogen atom of Xaa1, preferably Xaa1 is a residue of an α-L-amino acid selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya, Pse, Nmd and Ser, more preferably Xaa1 is a residue of an α-L-amino acid selected from the group consisting of Asp, Asn, Glu, and Gln, most preferably Xaa1 is an Asp residue.

5. The compound of any one of claims 1 to 4, wherein Xaa2 is a residue of an α-L-amino acid of formula (IIId),wherein X2a is NH or S, preferably is NH, R2a is H or F, 23R2b is selected from the group consisiting of H, F and Cl, R2c is selected from the group consisting of H, F, Cl, Br and OH, preferably Xaa2 is a residue an α-L-amino acid selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, 5Clw, 5Brw and 6Fw, more preferably Xaa2 is a residue an α-L-amino acid selected from the group consisting of Trp, Hyw, 5Fw and 7Fw, most preferably Xaa2 is a Trp residue.

6. The compound of any one of claims 1 to 5, wherein Xaa3 is a residue of an amino acid of formula (IVe) or (IVf),wherein R3b is H or F, R3c is selected from the group consisting of Cl, Br, H and F, X3a is NH or S, X3b is selected from the group consisting of C-H, C-F and N, and X3c is C-H or N, preferably X3c is C-H, preferably Xaa3 is a residue of an α-L-amino acid selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw and 7Fw, more preferably Xaa3 is a residue of an α-L-amino acid selected from the group consisting of 5Clw and 5Brw, and most preferably Xaa3 is a 5Clw residue.

247. The compound of any one of claims 1 to 6, wherein Xaa4 is a residue of an α-L-amino acid of formula (Va)wherein m is 1 or 2, preferably m is 1, R4a is selected from the group consisting of H, OH and methyl, R4b is either H or methyl, preferably R4b is methyl if R4a is methyl, X4 is selected from the group consisting of CHR4c, CH2, S and O, wherein R4c is selected from the group consisting of NHR4d, NH2, H, OH, methyl and F, wherein R4d is Ac or is a Z group, preferably the Z group is a chelator optionally comprising a linker, more preferably the chelator is DOTA, preferably Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), 4Tfp and H3p, more preferably Xaa4 is a residue of an α-L-amino acid selected from the group consisting of Tap, Hyp, Pro and 4Ap, and most preferably Xaa4 is a Tap residue, or (b) Xaa4 is a residue of an N-alkylated α-amino acid of formula (Vf) 25wherein n is 0, 1 or 3, R4e if n = 0, is selected from the group consisting of H and phenyl, or if n = 1, is selected from the group consisting of methyl, CONH2 and COOH, or if n = 3, is selected from the group consisting of NH2and NHR4h, wherein R4h is a Z group, preferably the Z group is a bio-distribution modifier, R4f is selected from the group consisting of H and methyl, preferably Xaa4 is a residue of an N-alkylated α-amino acid selected from the group consisting of Nmg, Nlys, Nleu, Nphe and Nglu, or (c) Xaa4 is an Oic residue.

8. The compound of any one of claims 1 to 7, wherein Xaa5 is a residue of an α amino acid optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by a methyl group, preferably Xaa5 is a residue of an α-L-amino acid selected from the group consisiting of Glu, Gln, Asp, Asn, Ser, Hse, Trp, Lys, Arg, His, Hly, and Har, more preferably Xaa5 is an α-L-amino acid selected from the group consisiting of Glu, Gln, Asp, Asn, Ser, and Hse, most preferably Xaa5 is a Glu residue.

9. The compound of any one of claims 1 to 8, wherein Xaa6 is a residue of an amino acid of formula (VIIa) 26wherein p is 1 or 0, preferably p is 1, R6a is (C1-C2)alkyl, R6b is methyl, and R6c is H if p is 0, and is H or methyl, if p is 1, preferably Xaa6 is a residue of an α-amino acid selected from the group consisting of leu, Leu, Npg, Val, Ile and Hle, more preferably Xaa6 is a residue of an α-amino acid selected from the group consisting of leu, Leu, Npg, Val and Ile, and most preferably Xaa6 is a leu residue.

10. The compound of any one of claims 1 to 9, wherein Xaa8 is a residue of a cyclic α-amino acid of formula (IXa),wherein r is 2 or 1, preferably r is 2, X8 is selected from the group consisting of NR8a, O, NH, and CH2, wherein R8a is a Z group or R8a is acetyl, preferably R8a is a Z group, wherein the Z group is a chelator optionally comprising a linker, wherein more preferably the chelator is DOTA, 27preferably Xaa8 is a residue of a cyclic α-amino acid residue selected from the group consisting of Apc(R8a), Apc, and Thp, wherein R8a is a Z group, wherein if the Z group is a chelator optionally comprising a linker, preferably the chelator is DOTA, or R8a is acetyl, more preferably Xaa8 is Apc(R8a), wherein R8a is a Z group, wherein the Z group is a chelator optionally comprising a linker , wherein the chelator a) preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, b) more preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof, (b) Xaa8 is an Aic residue, (c) Xaa8 is a residue of an α-amino acid selected from the group consisting of Lys, Lys(R8e), lys(R8e), Amk(R8e), Dab(R8e) and dab(R8e), wherein R8e is a Z group, preferably the Z group is a chelator optionally comprising a linker, preferably Xaa8 is a Amk(R8e) residue, wherein R8e is a Z group, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator a) preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A”-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99mTc(CO)3-chelators and their analogs, 28b) more preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A”-DTPA, CB-TE2A, Macropa, PCTA, N4, and analogs thereof, and c) most preferably is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof, (d) Xaa8 is a residue of an α-amino acid residue selected from the group consisting of Aib, Deg, Ams, ala, Ala, Gln, Thr, Trp, Phe and Glu.

11. The compound of any one of claims 1 to 10, wherein Xaa9 is a residue of an amino acid of formula (Xa)wherein R9a is selected from the group consisting of (C1-C4)alkyl, COOH, CONH2, OH, NH2, NHC(=NH)NH2, an aryl ring and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indoyl, and cyclo-hexyl, R9b is methyl or H, R9c is H or methyl, and v is 0, 1, 2, preferably v is 1, preferably Xaa9 is a residue of an α-L-amino acid selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe, Ser, Cha, Npg and Tle, more preferably Xaa9 is a residue of an α-L-amino acid selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe and Ser, and most preferably Xaa9 is a Leu residue. 2912. The compound of any one of claims 1 to 11, wherein Xaa10 is a residue of an amino acid of formula (XIa)wherein R10a is selected from the group consisting of (C1-C2)alkyl and phenyl, preferably R10a is (C1-C2)alkyl, more preferably (C1-C2)alkyl is ethyl, R10b is selected from the group consisting of methyl and H, preferably R10b is methyl, R10c is selected from the group consisting of H and methyl, R10C is H, if w is 1, preferably R10c is H, and w is 0 or 1, preferably w is 0, preferably Xaa10 is a residue of an α-L-amino acid selected from the group consisting of Ile, Leu, Tle, Val, and Phe, more preferably Xaa10 is a residue of α-L-amino acid selected from the group consisting of Ile, Leu and Tle, most preferably Xaa10 is an Ile residue.

13. The compound of any one of claims 1 to 12, wherein the N-terminal modification group A wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between the bio-distribution modifier comprised by the N-terminal modification group A and Xaa1, wherein the bio-distribution modifier comprises a residue of an aliphatic carboxylic acid, wherein to an ω-carbon atom of the aliphatic carboxylic acid a nitrogen atom or a triazolyl moiety is covalently attached, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, 30or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, preferably the bio-distribution modifier is a structure of formula (A-I),wherein XA comprises a nitrogen atom or a triazolyl moiety, a1is 0, 1, 2, 3, 4, 5, or 6, if XA is a triazolyl moiety, preferably a1 is 2, if XA is a nitrogen atom, preferably a1 is 4, RA1 is a first level alkyl group of a structure of formula (A-II),wherein b1 is 0 or 1, wherein, if b1 is 0, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III), or RA3 and RA4 are each H, or wherein, if b1is 1, each and any of RA3, RA4 and RA5 is individually and independently selected from a second level alkyl group of a structure of formula (A-III) and H, preferably each and any of RA3, RA4 and RA5 is individually and independently a second level alkyl group of a structure of formula (A-III), 31and wherein RA2 is absent, if XA is a triazolyl moiety, or RA2 a first level alkyl group of a structure of formula (A-II), if XA is a nitrogen atom, wherein b1is 0, wherein, RA3 and RA4 are individually and independently a second level alkyl group of a structure of formula (A-III) or RA3 and RA4 are each H, and wherein the carbonyl group of the structure (A-I) is covalently attached to the α-nitrogen atom of Xaa1, or if a linker, comprising an amino group and a carbonyl group, is interspersed between the bio- distribution modifier comprised by the N-terminal modification group A and Xaa1, the carbonyl group of the structure (A-I) is covalently attached to the amino group of the linker, wherein if to the ω-carbon atom of the aliphatic carboxylic acid a) a nitrogen atom is covalently attached, the N-terminal modification group A is selected from the group consisting of HPD2:Ahx and HPD4:HPD2:Ahx, or b) a triazolyl moiety is covalently attached, the N-terminal modification group A is selected from the group consisting of HPD3:PEO:Hyx and HPD2:HPD:Hyx, and wherein a linker comprising an amino group and a carbonyl group is optionally interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, wherein the bio-distribution modifier comprises a residue of an α-amino acid with an aliphatic side chain, wherein to an ω-carbon atom of the aliphatic side chain of the α-amino acid a nitrogen atom or a triazolyl moiety is covalently attached, wherein to the nitrogen atom or to the triazolyl moiety (a) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, 32or, (b) 1 or 2 first level alkyl groups are covalently attached, wherein each and any first level alkyl group is covalently attached via an ether linkage to 1 or more second level alkyl groups, wherein each and any second level alkyl group individually and independently comprises 2 or more hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein each and any first level alkyl group individually and independently comprises 0, 1 or 2 hydroxyl groups, wherein each and any hydroxyl group is a primary hydroxyl group, and wherein to the carbonyl group of the α-amino acid an amino group is covalently attached thereby forming an amide, preferably the bio-distribution modifier is a structure of formula (C-I),wherein XC comprises a nitrogen atom or a triazolyl moiety, a4 is 0, 1, 2, 3, or 4, if XC is a triazolyl moiety, preferably a4 is 1 or 2, more preferably a4 is 1 if XC is a nitrogen atom, preferably a4is 3, RC1 is a first level alkyl group of a structure of formula (C-II),wherein b3is 0 or 1, wherein, if b3is 0, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are each H, or wherein, if b is 1, each and any of RC3, RC4 an C5 3 d R is selected from a second level alkyl group of a structure of formula (C-III) and H, preferably each and any of RC3, RC4 and RC5 is individually and independently a second level alkyl group of a structure of formula (C-III), 33and RC2 is absent, if XC is a triazolyl moiety, or RC2 is a first level alkyl group of a structure of formula (C-II), if XC is a nitrogen atom, wherein b3 is 0, wherein, RC3 and RC4 are individually and independently a second level alkyl group of a structure of formula (C-III) or RC3 and RC4 are each H, and wherein the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of Xaa11, or if a linker comprising an amino group and a carbonyl group is interspersed between Xaa11 and the bio-distribution modifier comprised by the C-terminal modification group C-term, the α-nitrogen atom of the structure (C-I) is covalently attached to the carbonyl group of the linker, more preferably the linker is interspersed between Xaa11 and the bio-distribution comprised by the C-terminal modification group C-term, wherein if to the ω-carbon atom of the aliphatic side chain of the α-amino acid a) a nitrogen atom is covalently attached, the C-terminal modification group C-term is selected from the group consisting of lys:HPD2 and lys:HPD2:HPD4, or b) a triazolyl moiety is covalently attached, the C-terminal modification group C-term is selected from the group consisting of prx:TRIS:HPD3 and prx:HPD:HPD2.

14. The compound of any one of claims 1 to 13, wherein the compound comprises three or four Z groups; preferably the compound comprises three Z-groups, wherein a first of the three Z groups is the Z group comprised by the N-terminal modification group A, wherein the Z group comprises a bio-distribution modifier optionally comprising a linker, and a second of the three Z groups is the Z group comprised by the C-terminal modification group C-term, wherein the Z group comprises a bio-distribution modifier optionally comprising a linker, and a third of the three Z groups is covalently attached to or is part of substituent R8a, under the proviso that Xaa8 is a structure of formula (IXa), 34or is covalently attached to or is part of substituent R8e, under the proviso that Xaa8 is selected from the group comprising Lys(R8e), lys(R8e), Amk(R8e), Dab(R8e) and dab(R8e), preferably each and any linker comprises an amino group and a carbonyl group.

15. The compound of any one of claims 1 to 14, wherein Xaa1 is Asp, Asn, Glu, Gln or Cya, Xaa2 is Trp, Hyw, 5Fw, 6Clw or 7Fw, Xaa3 is 5Clw, 5Brw, 5Fw, Trp, 1Ni, Bta, 6Fw or Trp, Xaa4 is Tap, Hyp, 4Tfp, Pro, H3p, Eaz, Oxa, Dtc, Nmg, Nleu, Nlys, Nphe or Nglu, Xaa5 is Glu, glu, Nme, Gln, Asp, Asn or Hse, Xaa6 is leu, Leu, Npg, Val or Ile, Xaa7 is Cys or Hcy, Dap Xaa8 is Apc(DOTA), Thp, Apc, Aib, Deg, Ams, Amk(DOTA), Egz, Eca, or ala, Xaa9 is Leu, Hle, Ile, Phe, Glu, Arg, Ser or Trp, Xaa10 is Ile, Leu, Val or Tle, Xaa11 is Cys, Hcy, Dap and Yc is 3MeBn or 3Lut, or wherein Xaa1 is Asp or Glu, Xaa2 is Trp or Hyw, Xaa3 is 5Clw or 5Brw, Xaa4 is Tap, Hyp, or Pro, Xaa5 is Glu, Xaa6 is leu or Leu, Xaa7 is Cys, Xaa8 is Apc(DOTA) or Amk(DOTA), Xaa9 is Leu, Xaa10 is Ile Xaa11 is Cys and Yc is 3Lut, 35or wherein Xaa1 is Asp, Xaa2 is Trp, Xaa3 is 5Clw, Xaa4 is Tap or Hyp, Xaa5 is Glu, Xaa6 is leu, Xaa7 is Cys, Xaa8 is Apc(DOTA), Xaa9 is Leu, Xaa10 is Ile Xaa11 is Cys and Yc is 3Lut, preferably the compound comprises three Z groups, wherein a first of the three Z groups is a bio-distribution modifier, wherein the bio-distribution modifier forms the N-terminal modification group A, wherein the bio-distribution modifier is selected from the group consisting of HPD2:Ahx, HPD3:PEO:Hyx, HPD2:HPD:Hyx and HPD4:HPD2:Ahx and wherein a second of the three Z groups is a bio-distribution modifier optionally comprising a linker, wherein the bio-distribution modifier and the linker form the C-terminal group C-term, wherein the linker is APAc and wherein the bio-distribution modifier is selected from the group consisting of lys:HPD2, prx:PEO:HPD3, prx:HPD:HPD2 and lys:HPD2:HPD4, and wherein a third of the three Z groups is a chelator, wherein the chelator is covalently attached to Xaa8, wherein the Xaa8 is Apc and wherein the chelator is DOTA.

16. The compound of any one of claims 1 to 15, wherein the compound is selected from the group consisting of compound HPD2:Ahx-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile- Cys]-APAc-lys:HPD2 (GIP-1001) of the following formula 36, compound HPD3:PEO:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:PEO:HPD3 (GIP-1030) of the following formula, compound HPD2:HPD:Hyx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-prx:HPD:HPD2 (GIP-1077) of the following formula 37, and compound HPD4:HPD2:Ahx-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]- APAc-lys:HPD2:HPD4 (GIP-1078) of the following formula. 3817. The compound of any one of claims 1 to 16, wherein any S-atom, which can be oxidized, preferably any S atom of a thioether group, is present as -S-, -S(O)- or S(O2)- or mixture thereof.

18. The compound of any one of claims 1 to 17, wherein the compound comprises a radionuclide, wherein the radionuclide is a radionuclide suitable for diagnosis of a disease; preferably the radionuclide is selected from the group comprising, 43Sc, 44Sc, 51Mn, 52Mn, 64Cu, 67Ga, 68Ga, 86Y, 89Zr, 94mTc, 99mTc, 111In, 152Tb, 155Tb, 177Lu, 201Tl, 203Pb,18F, 76Br, 77Br, 123I, 124I, and 125I, more preferably is selected from the group comprising 43Sc, 44Sc, 64Cu, 67Ga, 68Ga, 86Y,89Zr, 111In, 152Tb, 155Tb, and 203Pb, and most preferably is selected from the group comprising 64Cu, 68Ga, 111In and 203Pb.

19. The compound of any one of claims 1 to 17, wherein the compound comprises a radionuclide, wherein the radionuclide is a radionuclide suitable for the treatment of a disease; preferably the radionuclide is selected from the group comprising 47Sc, 67Cu, 89Sr, 90Y, 111In, 153Sm, 149Tb, 161Tb, 177Lu, 186Re, 188Re, 212Pb, 213Bi, 223Ra, 225Ac, 226Th, 227Th, 131I, and 211At, more preferably is selected from the group comprising 47Sc, 67Cu, 90Y, 177Lu, 212Pb, 213Bi, 225Ac, and 227Th, and most preferably is selected from the group comprising 90Y, 177Lu, 212Pb, 225Ac, and 227Th.

20. The compound of any one of claims 1 to 18, for use in a method for diagnosing a disease.

21. The compound of any one of claims 1 to 17 and 19, for use in a method for the treatment of a disease.

22. The compound of any one of claims 1 to 18, for use in a method for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the identification of a subject comprises carrying out a method of diagnosing a disease using a compound of any one of claims 1 to 18, or for use in a method 39for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of a disease, wherein the method for the selection of a subject from a group of subjects comprises carrying out a method of diagnosing a disease using a compound of any one of claims 1 to 18 or for use in a method for the stratification of a group of subjects into subjects which are likely to respond to a treatment of a disease, and into subjects which are not likely to respond to a treatment of a disease, wherein the method for the stratification of a group of subjects comprises carrying out a method of diagnosing a disease using a compound of any one of claims 1 to 18.

23. The compound for use of any one of claims 20 to 22, wherein the disease is cancer, preferably the cancer is expressing Gastric Inhibitory Peptide Receptor (GIPR), more preferably the cancer is overexpressing GIPR.

24. The compound for use of claim 23, wherein the cancer is a neuroendocrine cancer or a neuroendocrine neoplasm, preferably the cancer is selected from the group consisting of medullary thyroid cancer, gastrointestinal neuroendocrine neoplasms, ileal neuroendocrine neoplasms, pancreatic neuroendocrine neoplasms, nonfunctioning neuroendocrine neoplasms, Insulinomas, Gastrinomas, Glucagonomas, VIPomas, Somatostatinoma, ACTHoma, lung neuroendocrine neoplasms, typical carcinoid tumors, atypical carcinoid tumors, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumors, Merkel cell carcinoma, Pheochromocytoma of the adrenal gland, adrenal cancer, parathyroid cancer, paraganglioma, pituitary gland tumors, neuroendocrine tumors of the ovaries and neuroendocrine tumors of the testicles.

25. The compound for use of any one of claims 20 to 22, wherein the disease is a metabolic disease, preferably a diseased cell and / or a diseased tissue, preferably a diseased cell and / or a diseased tissue of the metabolic disease expresses GIPR; more preferably the diseased cell and / or the diseased tissue overexpresses GIPR; most preferably the diseased cell is a pancreatic cell.

26. The compound for use of claim 25, wherein the metabolic disease is selected from the group consisting of type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose, and impaired glucose tolerance. 4027. A composition comprising a compound of any one of claims 1 to 19 and a pharmaceutically acceptable excipient; preferably the composition is a pharmaceutical composition.

28. A kit comprising a compound of any one of claims 1 to 19 and one or more optional excipient(s) and optionally one or more device(s); preferably the device(s) is / are selected from the group comprising a labelling device, a purification device, a handling device, a radioprotection device, an analytical device or an administration device. 41

Images